<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Bull World Health Organ</journal-id><journal-id journal-id-type="iso-abbrev">Bull. World Health Organ</journal-id><journal-id journal-id-type="publisher-id">BLT</journal-id><journal-title-group><journal-title>Bulletin of the World Health Organization</journal-title></journal-title-group><issn pub-type="ppub">0042-9686</issn><issn pub-type="epub">1564-0604</issn><publisher><publisher-name>World Health Organization</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26478610</article-id><article-id pub-id-type="pmc">4581655</article-id><article-id pub-id-type="publisher-id">BLT.14.147447</article-id><article-id pub-id-type="doi">10.2471/BLT.14.147447</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Monitoring of HIV treatment in seven countries in the WHO Region of the Americas</article-title><trans-title-group xml:lang="fr"><trans-title xml:lang="fr">Suivi du traitement du VIH dans sept pays de la R&#x000e9;gion OMS des Am&#x000e9;riques</trans-title></trans-title-group><trans-title-group xml:lang="es"><trans-title xml:lang="es">Monitoreo del tratamiento del VIH en siete pa&#x000ed;ses de la Regi&#x000f3;n de las Am&#x000e9;ricas de la OMS</trans-title></trans-title-group><trans-title-group xml:lang="ar"><trans-title xml:lang="ar">&#x00645;&#x00631;&#x00627;&#x00642;&#x00628;&#x00629; &#x00639;&#x00644;&#x00627;&#x0062c; &#x00645;&#x00631;&#x00636; &#x00639;&#x00648;&#x00632; &#x00627;&#x00644;&#x00645;&#x00646;&#x00627;&#x00639;&#x00629; &#x00627;&#x00644;&#x00628;&#x00634;&#x00631;&#x0064a; &#x00641;&#x0064a; &#x00633;&#x00628;&#x00639; &#x00628;&#x00644;&#x0062f;&#x00627;&#x00646; &#x0064a;&#x00634;&#x00645;&#x00644;&#x00647;&#x00627; &#x00646;&#x00637;&#x00627;&#x00642; &#x00639;&#x00645;&#x00644; &#x00645;&#x00646;&#x00638;&#x00645;&#x00629;&#x000a0;&#x00627;&#x00644;&#x00635;&#x0062d;&#x00629;&#x000a0;&#x00627;&#x00644;&#x00639;&#x00627;&#x00644;&#x00645;&#x0064a;&#x00629;&#x000a0;&#x00641;&#x0064a;&#x000a0;&#x00627;&#x00644;&#x00623;&#x00645;&#x00631;&#x0064a;&#x00643;&#x0062a;&#x0064a;&#x00646; </trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title xml:lang="zh">&#x04e03;&#x04e2a;&#x04e16;&#x0754c;&#x0536b;&#x0751f;&#x07ec4;&#x07ec7;&#x07f8e;&#x06d32;&#x0533a;&#x057df;&#x056fd;&#x05bb6;&#x07684;&#x000a0;HIV&#x000a0;&#x06cbb;&#x07597;&#x076d1;&#x06d4b;</trans-title></trans-title-group><trans-title-group xml:lang="ru"><trans-title xml:lang="ru">&#x0041d;&#x00430;&#x00431;&#x0043b;&#x0044e;&#x00434;&#x00435;&#x0043d;&#x00438;&#x00435; &#x00437;&#x00430; &#x0043b;&#x00435;&#x00447;&#x00435;&#x0043d;&#x00438;&#x00435;&#x0043c;&#x000a0;&#x00412;&#x00418;&#x00427; &#x00432; &#x00441;&#x00435;&#x0043c;&#x00438; &#x00441;&#x00442;&#x00440;&#x00430;&#x0043d;&#x00430;&#x00445; &#x00430;&#x0043c;&#x00435;&#x00440;&#x00438;&#x0043a;&#x00430;&#x0043d;&#x00441;&#x0043a;&#x0043e;&#x00433;&#x0043e; &#x00440;&#x00435;&#x00433;&#x00438;&#x0043e;&#x0043d;&#x00430;&#x000a0;&#x00412;&#x0041e;&#x00417;</trans-title></trans-title-group><alt-title alt-title-type="author-running-head">Pablo F Belaunzar&#x000e1;n-Zamudio et al.</alt-title><alt-title alt-title-type="title-running-head">HIV treatment monitoring in the Americas</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Belaunzar&#x000e1;n-Zamudio</surname><given-names>Pablo F</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Caro-Vega</surname><given-names>Yanink N</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Shepherd</surname><given-names>Bryan E</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Crabtree-Ram&#x000ed;rez</surname><given-names>Brenda E</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Luz</surname><given-names>Paula M</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Grinsztejn</surname><given-names>Beatriz</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cesar</surname><given-names>Carina</given-names></name><xref ref-type="aff" rid="aff4"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cahn</surname><given-names>Pedro</given-names></name><xref ref-type="aff" rid="aff4"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cort&#x000e9;s</surname><given-names>Claudia</given-names></name><xref ref-type="aff" rid="aff5"><sup>e</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wolff</surname><given-names>Marcelo</given-names></name><xref ref-type="aff" rid="aff5"><sup>e</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pape</surname><given-names>Jean W</given-names></name><xref ref-type="aff" rid="aff6"><sup>f</sup></xref></contrib><contrib contrib-type="author"><name><surname>Padgett</surname><given-names>Denis</given-names></name><xref ref-type="aff" rid="aff7"><sup>g</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gotuzzo</surname><given-names>Eduardo</given-names></name><xref ref-type="aff" rid="aff8"><sup>h</sup></xref></contrib><contrib contrib-type="author"><name><surname>McGowan</surname><given-names>Catherine</given-names></name><xref ref-type="aff" rid="aff9"><sup>i</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sierra-Madero</surname><given-names>Juan G</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><collab>on behalf of CCASAnet</collab></contrib><aff id="aff1"><label>a</label>Cl&#x000ed;nica de Inmuno-Infectolog&#x000ed;a, Departamento de Infectolog&#x000ed;a, Instituto Nacional de Ciencias M&#x000e9;dicas y Nutrici&#x000f3;n Salvador Zubir&#x000e1;n, Calle Vasco de Quiroga 15, Colonia Belisario Dom&#x000ed;nguez Secci&#x000f3;n XVI, Delegaci&#x000f3;n Tlalpan, M&#x000e9;xico Distrito Federal, CP 14080, <country>Mexico</country>.</aff><aff id="aff2"><label>b</label>Department of Biostatistics, Vanderbilt University, Nashville, United States of America (USA).</aff><aff id="aff3"><label>c</label>Instituto de Pesquisa Cl&#x000ed;nica Evandro Chagas, Fundac&#x000e3;o Oswaldo Cruz, Rio de Janeiro, <country>Brazil</country>.</aff><aff id="aff4"><label>d</label>Fundaci&#x000f3;n Hu&#x000e9;sped, Buenos Aires, <country>Argentina</country>.</aff><aff id="aff5"><label>e</label>Fundaci&#x000f3;n Arriar&#x000e1;n, Universidad de Chile, Santiago, <country>Chile</country>.</aff><aff id="aff6"><label>f</label>Le Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes, Port-au-Prince, <country>Haiti</country>.</aff><aff id="aff7"><label>g</label>Instituto Hondure&#x000f1;o de Seguridad Social and Hospital Escuela, Tegucigalpa, <country>Honduras</country>.</aff><aff id="aff8"><label>h</label>Instituto de Medicina Tropical Alexander von Humboldt, Lima, <country>Peru</country>.</aff><aff id="aff9"><label>i</label>Department of Medicine, Vanderbilt University, Nashville, <country>USA</country>.</aff></contrib-group><author-notes><corresp id="cor1">Correspondence to Yanink N Caro-Vega (email: <email xlink:href="yaninkc@yahoo.com.mx">yaninkc@yahoo.com.mx</email>).</corresp></author-notes><pub-date pub-type="ppub"><day>01</day><month>8</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>27</day><month>5</month><year>2015</year></pub-date><volume>93</volume><issue>8</issue><fpage>529</fpage><lpage>539</lpage><history><date date-type="received"><day>22</day><month>9</month><year>2014</year></date><date date-type="rev-recd"><day>18</day><month>3</month><year>2015</year></date><date date-type="accepted"><day>19</day><month>3</month><year>2015</year></date></history><permissions><copyright-statement>(c) 2015 The authors; licensee World Health Organization.</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution IGO License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/igo/legalcode">http://creativecommons.org/licenses/by/3.0/igo/legalcode</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any reproduction of this article there should not be any suggestion that WHO or this article endorse any specific organization or products. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL.</license-p></license></permissions><abstract><title>Abstract</title><sec><title>Objective</title><p>To determine the prevalence of adequate monitoring and the costs of measuring CD4+ T-lymphocytes (CD4+ cell) and human immunodeficiency virus (HIV) viral load in people receiving antiretroviral therapy (ART) in seven countries in the WHO Region of the Americas.</p></sec><sec><title>Methods</title><p>We obtained retrospective, longitudinal data for 14&#x02009;476 adults who started a first ART regimen at seven HIV clinics in Argentina, Brazil, Chile, Haiti, Honduras, Mexico and Peru between 2000 and 2011. We estimated the proportion of 180-day periods with adequate monitoring, which we defined as at least one CD4+ cell count and one viral load measurement. Factors associated with adequate monitoring were analysed using regression methods. The costs of the tests were estimated.</p></sec><sec><title>Findings</title><p>The median follow-up time was 50.4&#x000a0;months; the proportion of 180-day periods with adequate CD4+ cell counts was 69% while the proportion with adequate monitoring was 62%. Adequate monitoring was more likely in participants who were older, who started ART more recently, whose first regimen included a non-nucleoside reverse transcriptase inhibitor or who had a CD4+ cell count less than 200&#x000a0;cells/&#x000b5;l at ART initiation. The cost of one CD4+ cell count ranged from 7.37 United States dollars (US$) in Argentina to US$&#x000a0;64.09 in Chile; the cost of one viral load measurement ranged from US$&#x000a0;20.34 in Brazil to US$&#x000a0;186.28 in Haiti.</p></sec><sec><title>Conclusion</title><p>In HIV-infected participants receiving ART in the WHO Region of the Americas, CD4+ cell count and viral load monitoring was often carried out less frequently than regional guidelines recommend. The laboratory costs of monitoring varied greatly.</p></sec></abstract><trans-abstract xml:lang="fr"><title>R&#x000e9;sum&#x000e9;</title><sec><title>Objectif</title><p>V&#x000e9;rifier l'existence d'un suivi ad&#x000e9;quat et d&#x000e9;terminer les co&#x000fb;ts li&#x000e9;s &#x000e0; la mesure des lymphocytes T CD4+ (cellule CD4+) et de la charge virale en virus de l'immunod&#x000e9;ficience humaine (VIH) chez des individus recevant un traitement antir&#x000e9;troviral (TAR) dans sept pays de la R&#x000e9;gion OMS des Am&#x000e9;riques.</p></sec><sec><title>M&#x000e9;thodes</title><p>Nous avons recueilli des donn&#x000e9;es r&#x000e9;trospectives et longitudinales sur 14&#x000a0;476&#x000a0;adultes ayant commenc&#x000e9; un sch&#x000e9;ma de TAR de premi&#x000e8;re intention dans sept centres de traitement du VIH situ&#x000e9;s en Argentine, au Br&#x000e9;sil, au Chili, &#x000e0; Ha&#x000ef;ti, au Honduras, au Mexique et au P&#x000e9;rou entre 2000&#x000a0;et 2011. Nous avons estim&#x000e9; la proportion de p&#x000e9;riodes de 180&#x000a0;jours caract&#x000e9;ris&#x000e9;es par un suivi ad&#x000e9;quat, lequel consistant au minimum en une num&#x000e9;ration des CD4+ et en une mesure de la charge virale. Les facteurs associ&#x000e9;s au suivi ad&#x000e9;quat ont &#x000e9;t&#x000e9; analys&#x000e9;s &#x000e0; l'aide de m&#x000e9;thodes de r&#x000e9;gression. Une estimation du co&#x000fb;t des tests a &#x000e9;t&#x000e9; effectu&#x000e9;e.</p></sec><sec><title>R&#x000e9;sultats</title><p>La dur&#x000e9;e moyenne du suivi &#x000e9;tait de 50,4&#x000a0;mois; la proportion des p&#x000e9;riodes de 180&#x000a0;jours caract&#x000e9;ris&#x000e9;es par une num&#x000e9;ration ad&#x000e9;quate des CD4+ &#x000e9;tait de 69%&#x000a0;alors que la proportion des p&#x000e9;riodes caract&#x000e9;ris&#x000e9;es par un suivi ad&#x000e9;quat &#x000e9;tait de 62%. Le suivi ad&#x000e9;quat concernait davantage les participants plus &#x000e2;g&#x000e9;s, ayant commenc&#x000e9; un TAR plus r&#x000e9;cemment et dont le sch&#x000e9;ma de premi&#x000e8;re intention incluait un inhibiteur non nucl&#x000e9;osidique de la transcriptase inverse ou dont la num&#x000e9;ration des CD4+ &#x000e9;tait inf&#x000e9;rieure &#x000e0; 200&#x000a0;cellules/&#x000b5;l au d&#x000e9;but du TAR. Le co&#x000fb;t d'une num&#x000e9;ration des CD4+ variait de 7,37&#x000a0;dollars des &#x000c9;tats-Unis (US$) en Argentine &#x000e0; 64,09&#x000a0;US$ au Chili; le co&#x000fb;t de la mesure d'une charge virale variait de 20,34&#x000a0;US$ au Br&#x000e9;sil &#x000e0; 186,28&#x000a0;US$ &#x000e0; Ha&#x000ef;ti.</p></sec><sec><title>Conclusion</title><p>En r&#x000e8;gle g&#x000e9;n&#x000e9;rale, le suivi de la num&#x000e9;ration des CD4+ et de la charge virale chez les participants infect&#x000e9;s par le VIH et recevant un TAR dans la R&#x000e9;gion OMS des Am&#x000e9;riques n'&#x000e9;tait pas r&#x000e9;alis&#x000e9; aussi souvent que ce que recommandent les directives r&#x000e9;gionales. Les frais de laboratoire li&#x000e9;s au suivi variaient consid&#x000e9;rablement.</p></sec></trans-abstract><trans-abstract xml:lang="es"><title>Resumen</title><sec><title>Objetivo</title><p>Determinar la prevalencia de un monitoreo adecuado y los costes de medici&#x000f3;n de los linfocitos T CD4+ (c&#x000e9;lula CD4+) y la carga viral del virus de inmunodeficiencia humana (VIH) en personas que reciben terapia antirretroviral (TAR) en siete pa&#x000ed;ses de la Regi&#x000f3;n de las Am&#x000e9;ricas de la OMS.</p></sec><sec><title>M&#x000e9;todos</title><p>Se obtuvieron datos retrospectivos y longitudinales de 14.476 adultos que comenzaban un primer r&#x000e9;gimen de TAR en siete cl&#x000ed;nicas de VIH en Argentina, Brasil, Chile, Hait&#x000ed;, Honduras, M&#x000e9;xico y Per&#x000fa; entre 2000 y 2011. Se estim&#x000f3; la proporci&#x000f3;n de periodos de 180 d&#x000ed;as con un monitoreo adecuado, lo que se defini&#x000f3; como al menos un recuento de c&#x000e9;lulas CD4+ y una medici&#x000f3;n de la carga viral. Se analizaron factores relacionados con un monitoreo adecuado mediante la utilizaci&#x000f3;n de m&#x000e9;todos de regresi&#x000f3;n. Se estimaron los costes de las pruebas.</p></sec><sec><title>Resultados</title><p>La mediana de tiempo de monitoreo fue de 50,4 meses; la proporci&#x000f3;n de periodos de 180 d&#x000ed;as con recuentos de c&#x000e9;lulas CD4+ adecuados fue del 69%, mientras que la proporci&#x000f3;n de un monitoreo adecuado fue del 62%. Un monitoreo adecuado era m&#x000e1;s propenso en participantes mayores, que hab&#x000ed;an comenzado el TAR m&#x000e1;s recientemente, cuyo primer r&#x000e9;gimen inclu&#x000ed;a un inhibidor de la transcriptasa inversa no nucle&#x000f3;sido o que ten&#x000ed;an un recuento de c&#x000e9;lulas CD4+ menor de 200 c&#x000e9;lulas/&#x000b5;l en el inicio del TAR. El coste de un recuento de c&#x000e9;lulas CD4+ comprend&#x000ed;a desde los 7,37 d&#x000f3;lares de los Estados Unidos (USD) en Argentina a los 64,09 USD en Chile; el coste de una medici&#x000f3;n de la carga viral comprend&#x000ed;a desde los 20,34 USD en Brasil a los 186,28 USD en Hait&#x000ed;.</p></sec><sec><title>Conclusi&#x000f3;n</title><p>Entre los participantes infectados por el VIH que recib&#x000ed;an el TAR en la Regi&#x000f3;n, el recuento de c&#x000e9;lulas CD4+ y la medici&#x000f3;n de la carga viral eran a menudo realizadas con menor frecuencia que la recomendada por las directrices regionales. Los costes de laboratorio del monitoreo variaban considerablemente.</p></sec></trans-abstract><trans-abstract xml:lang="ar"><title>&#x00645;&#x00644;&#x0062e;&#x00635; </title><sec><title>&#x00627;&#x00644;&#x0063a;&#x00631;&#x00636; </title><p>&#x0062a;&#x0062d;&#x0062f;&#x0064a;&#x0062f; &#x00645;&#x0062f;&#x00649; &#x00627;&#x00646;&#x0062a;&#x00634;&#x00627;&#x00631; &#x00627;&#x00644;&#x00645;&#x00631;&#x00627;&#x00642;&#x00628;&#x00629; &#x00627;&#x00644;&#x00645;&#x00646;&#x00627;&#x00633;&#x00628;&#x00629; &#x00648;&#x0062a;&#x00643;&#x00627;&#x00644;&#x0064a;&#x00641; &#x00642;&#x0064a;&#x00627;&#x00633; &#x00645;&#x0062f;&#x00649; &#x00648;&#x0062c;&#x00648;&#x0062f; &#x00627;&#x00644;&#x0062e;&#x00644;&#x00627;&#x0064a;&#x00627; &#x00627;&#x00644;&#x00644;&#x00645;&#x00641;&#x0064a;&#x00629; &#x00627;&#x00644;&#x0062a;&#x00627;&#x00626;&#x0064a;&#x00629; &#x00645;&#x00646; &#x00641;&#x00626;&#x00629; CD4+&#x0200e; (&#x0062e;&#x00644;&#x00627;&#x0064a;&#x00627; &#x00641;&#x00626;&#x00629; CD4+&#x0200e;) &#x00648;&#x00642;&#x0064a;&#x00627;&#x00633; &#x00627;&#x00644;&#x0062d;&#x00645;&#x00644; &#x00627;&#x00644;&#x00641;&#x0064a;&#x00631;&#x00648;&#x00633;&#x0064a; &#x00627;&#x00644;&#x00645;&#x0062a;&#x00639;&#x00644;&#x00642; &#x00628;&#x00641;&#x0064a;&#x00631;&#x00648;&#x00633; &#x00639;&#x00648;&#x00632; &#x00627;&#x00644;&#x00645;&#x00646;&#x00627;&#x00639;&#x00629; &#x00627;&#x00644;&#x00628;&#x00634;&#x00631;&#x0064a; (HIV) &#x00641;&#x0064a; &#x00627;&#x00644;&#x00623;&#x00634;&#x0062e;&#x00627;&#x00635; &#x00627;&#x00644;&#x00630;&#x0064a;&#x00646; &#x0064a;&#x0062a;&#x00644;&#x00642;&#x00648;&#x00646; &#x00639;&#x00644;&#x00627;&#x0062c;&#x0064b;&#x00627; &#x00628;&#x00627;&#x00633;&#x0062a;&#x0062e;&#x0062f;&#x00627;&#x00645; &#x00645;&#x00636;&#x00627;&#x0062f;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00641;&#x0064a;&#x00631;&#x00648;&#x00633;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00642;&#x00647;&#x00642;&#x00631;&#x0064a;&#x00629; (ART) &#x00641;&#x0064a; &#x00633;&#x00628;&#x00639; &#x00628;&#x00644;&#x0062f;&#x00627;&#x00646; &#x0064a;&#x00634;&#x00645;&#x00644;&#x00647;&#x00645; &#x00646;&#x00637;&#x00627;&#x00642; &#x00639;&#x00645;&#x00644; &#x00645;&#x00646;&#x00638;&#x00645;&#x00629; &#x00627;&#x00644;&#x00635;&#x0062d;&#x00629; &#x00627;&#x00644;&#x00639;&#x00627;&#x00644;&#x00645;&#x0064a;&#x00629; &#x00641;&#x0064a; &#x00627;&#x00644;&#x00623;&#x00645;&#x00631;&#x0064a;&#x00643;&#x0062a;&#x0064a;&#x00646;. </p></sec><sec><title>&#x00627;&#x00644;&#x00637;&#x00631;&#x0064a;&#x00642;&#x00629; </title><p>&#x0062d;&#x00635;&#x00644;&#x00646;&#x00627; &#x00639;&#x00644;&#x00649; &#x00628;&#x0064a;&#x00627;&#x00646;&#x00627;&#x0062a; &#x00637;&#x00648;&#x00644;&#x00627;&#x00646;&#x0064a;&#x00629; &#x00628;&#x00623;&#x0062b;&#x00631; &#x00631;&#x0062c;&#x00639;&#x0064a; &#x00628;&#x00634;&#x00623;&#x00646;&#x000a0;14476 &#x00645;&#x00646; &#x00627;&#x00644;&#x00628;&#x00627;&#x00644;&#x0063a;&#x0064a;&#x00646; &#x00627;&#x00644;&#x00630;&#x0064a;&#x00646; &#x00628;&#x0062f;&#x00623;&#x00648;&#x00627; &#x00641;&#x0064a; &#x0062e;&#x00637;&#x00629; &#x00639;&#x00644;&#x00627;&#x0062c; ART &#x00644;&#x00644;&#x00645;&#x00631;&#x00629; &#x00627;&#x00644;&#x00623;&#x00648;&#x00644;&#x00649; &#x00641;&#x0064a; &#x00633;&#x00628;&#x00639; &#x00639;&#x0064a;&#x00627;&#x0062f;&#x00627;&#x0062a; &#x00644;&#x00639;&#x00644;&#x00627;&#x0062c; &#x00639;&#x00648;&#x00632; &#x00627;&#x00644;&#x00645;&#x00646;&#x00627;&#x00639;&#x00629; &#x00627;&#x00644;&#x00628;&#x00634;&#x00631;&#x0064a; &#x00641;&#x0064a; &#x00627;&#x00644;&#x00623;&#x00631;&#x0062c;&#x00646;&#x0062a;&#x0064a;&#x00646;&#x0060c; &#x00648;&#x00627;&#x00644;&#x00628;&#x00631;&#x00627;&#x00632;&#x0064a;&#x00644;&#x0060c; &#x00648;&#x00634;&#x0064a;&#x00644;&#x0064a;&#x0060c; &#x00648;&#x00647;&#x00627;&#x0064a;&#x0062a;&#x0064a;&#x0060c; &#x00648;&#x00647;&#x00646;&#x0062f;&#x00648;&#x00631;&#x00627;&#x00633;&#x0060c; &#x00648;&#x00627;&#x00644;&#x00645;&#x00643;&#x00633;&#x0064a;&#x00643;&#x0060c; &#x00648;&#x00628;&#x0064a;&#x00631;&#x00648; &#x00641;&#x0064a; &#x00627;&#x00644;&#x00641;&#x0062a;&#x00631;&#x00629; &#x00628;&#x0064a;&#x00646; &#x00639;&#x00627;&#x00645;&#x000a0;2000 &#x00648;2011. &#x00648;&#x00623;&#x0062c;&#x00631;&#x0064a;&#x00646;&#x00627; &#x0062a;&#x00642;&#x0062f;&#x0064a;&#x00631;&#x0064b;&#x00627; &#x00644;&#x00646;&#x00633;&#x00628;&#x00629; &#x00627;&#x00644;&#x00641;&#x0062a;&#x00631;&#x00627;&#x0062a; &#x00627;&#x00644;&#x0062a;&#x0064a; &#x0062a;&#x00628;&#x00644;&#x0063a; &#x00643;&#x00644; &#x00645;&#x00646;&#x00647;&#x00627; 180&#x000a0;&#x0064a;&#x00648;&#x00645;&#x0064b;&#x00627; &#x00648;&#x00627;&#x00644;&#x0062a;&#x0064a; &#x0062a;&#x00648;&#x00641;&#x00631;&#x0062a; &#x00628;&#x00647;&#x00627; &#x00637;&#x00631;&#x0064a;&#x00642;&#x00629; &#x00645;&#x00631;&#x00627;&#x00642;&#x00628;&#x00629; &#x00645;&#x00646;&#x00627;&#x00633;&#x00628;&#x00629;&#x0060c; &#x00648;&#x00627;&#x00644;&#x0062a;&#x0064a; &#x00639;&#x00631;&#x00651;&#x00641;&#x00646;&#x00627;&#x00647;&#x00627; &#x00628;&#x00623;&#x00646;&#x00647;&#x00627; &#x0062a;&#x00639;&#x0062f;&#x00627;&#x0062f; &#x00648;&#x00627;&#x0062d;&#x0062f; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x00623;&#x00642;&#x00644; &#x00644;&#x00644;&#x0062e;&#x00644;&#x00627;&#x0064a;&#x00627; &#x00641;&#x00626;&#x00629; CD4+&#x0200e;&#x0200e; &#x00648;&#x00642;&#x0064a;&#x00627;&#x00633;&#x0064b;&#x00627; &#x00648;&#x00627;&#x0062d;&#x0062f;&#x0064b;&#x00627; &#x00644;&#x00644;&#x0062d;&#x00650;&#x00645;&#x00644; &#x00627;&#x00644;&#x00641;&#x0064a;&#x00631;&#x00648;&#x00633;&#x0064a;. &#x00648;&#x0062a;&#x00645; &#x0062a;&#x0062d;&#x00644;&#x0064a;&#x00644; &#x00627;&#x00644;&#x00639;&#x00648;&#x00627;&#x00645;&#x00644; &#x00627;&#x00644;&#x00645;&#x00631;&#x0062a;&#x00628;&#x00637;&#x00629; &#x00628;&#x00627;&#x00644;&#x00645;&#x00631;&#x00627;&#x00642;&#x00628;&#x00629; &#x00627;&#x00644;&#x00645;&#x00646;&#x00627;&#x00633;&#x00628;&#x00629; &#x00628;&#x00627;&#x00633;&#x0062a;&#x0062e;&#x0062f;&#x00627;&#x00645; &#x00637;&#x00631;&#x00642; &#x00627;&#x00644;&#x0062a;&#x0062d;&#x00648;&#x00641;. &#x00643;&#x00645;&#x00627; &#x0062a;&#x00645; &#x0062a;&#x00642;&#x0062f;&#x0064a;&#x00631; &#x0062a;&#x00643;&#x00627;&#x00644;&#x0064a;&#x00641; &#x00627;&#x00644;&#x00627;&#x0062e;&#x0062a;&#x00628;&#x00627;&#x00631;&#x00627;&#x0062a;. </p></sec><sec><title>&#x00627;&#x00644;&#x00646;&#x0062a;&#x00627;&#x00626;&#x0062c; </title><p>&#x00628;&#x00644;&#x0063a; &#x00645;&#x0062a;&#x00648;&#x00633;&#x00637; &#x00641;&#x0062a;&#x00631;&#x00629; &#x00627;&#x00644;&#x00645;&#x0062a;&#x00627;&#x00628;&#x00639;&#x00629; 50.4 <bold>&#x000a0; </bold>&#x00634;&#x00647;&#x00631;&#x0064b;&#x00627;&#x0061b; &#x00648;&#x00648;&#x00635;&#x00644;&#x0062a; &#x00646;&#x00633;&#x00628;&#x00629; &#x00627;&#x00644;&#x00641;&#x0062a;&#x00631;&#x00627;&#x0062a; &#x00627;&#x00644;&#x0062a;&#x0064a; &#x0062a;&#x00628;&#x00644;&#x0063a; 180 <bold>&#x000a0; </bold>&#x0064a;&#x00648;&#x00645;&#x0064b;&#x00627; &#x00648;&#x00627;&#x00644;&#x0062a;&#x0064a; &#x0062a;&#x00645;&#x0064a;&#x00632;&#x0062a; &#x00628;&#x00648;&#x0062c;&#x00648;&#x0062f; &#x00639;&#x0062f;&#x0062f; &#x00645;&#x00646;&#x00627;&#x00633;&#x00628; &#x00645;&#x00646; &#x0062a;&#x00639;&#x0062f;&#x00627;&#x0062f; &#x00627;&#x00644;&#x0062e;&#x00644;&#x00627;&#x0064a;&#x00627; &#x00641;&#x00626;&#x00629; CD4+&#x0200e; &#x00625;&#x00644;&#x00649; <styled-content style-type="direction" style="direction:ltr;">69%</styled-content>&#x0060c; &#x00628;&#x0064a;&#x00646;&#x00645;&#x00627; &#x00628;&#x00644;&#x0063a;&#x0062a; &#x00646;&#x00633;&#x00628;&#x00629; &#x00627;&#x00644;&#x00645;&#x00631;&#x00627;&#x00642;&#x00628;&#x00629; &#x00627;&#x00644;&#x00645;&#x00646;&#x00627;&#x00633;&#x00628;&#x00629; <styled-content style-type="direction" style="direction:ltr;">62%</styled-content>. &#x00648;&#x00643;&#x00627;&#x00646; &#x00627;&#x0062d;&#x0062a;&#x00645;&#x00627;&#x00644; &#x0062a;&#x00637;&#x00628;&#x0064a;&#x00642; &#x00627;&#x00644;&#x00645;&#x00631;&#x00627;&#x00642;&#x00628;&#x00629; &#x00627;&#x00644;&#x00645;&#x00646;&#x00627;&#x00633;&#x00628;&#x00629; &#x00648;&#x00627;&#x00631;&#x0062f;&#x0064b;&#x00627; &#x00628;&#x0062f;&#x00631;&#x0062c;&#x00629; &#x00623;&#x00643;&#x00628;&#x00631; &#x00641;&#x0064a; &#x0062d;&#x00627;&#x00644;&#x00629; &#x00627;&#x00644;&#x00645;&#x00634;&#x00627;&#x00631;&#x00643;&#x0064a;&#x00646; &#x00627;&#x00644;&#x00623;&#x00643;&#x00628;&#x00631; &#x00633;&#x00646;&#x0064b;&#x00627; &#x00645;&#x00645;&#x00646; &#x00628;&#x0062f;&#x00623;&#x00648;&#x00627; &#x0062a;&#x00644;&#x00642;&#x0064a; ART &#x00645;&#x00624;&#x0062e;&#x00631;&#x0064b;&#x00627;&#x0060c; &#x00648;&#x00642;&#x0062f; &#x0062a;&#x00636;&#x00645;&#x00646;&#x0062a; &#x0062e;&#x00637;&#x00629; &#x00627;&#x00644;&#x00639;&#x00644;&#x00627;&#x0062c; &#x00627;&#x00644;&#x00623;&#x00648;&#x00644;&#x00649; &#x00644;&#x00647;&#x00645; &#x00627;&#x00633;&#x0062a;&#x0062e;&#x0062f;&#x00627;&#x00645; &#x00623;&#x0062d;&#x0062f; &#x00627;&#x00644;&#x00623;&#x0062f;&#x00648;&#x0064a;&#x00629; &#x0063a;&#x0064a;&#x00631; &#x00627;&#x00644;&#x00646;&#x0064a;&#x00648;&#x00643;&#x00644;&#x0064a;&#x00648;&#x00632;&#x0064a;&#x0062f;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00645;&#x00636;&#x00627;&#x0062f;&#x00629; &#x00644;&#x00625;&#x00646;&#x00632;&#x0064a;&#x00645; &#x00627;&#x00644;&#x00645;&#x00646;&#x0062a;&#x00633;&#x0062e;&#x00629; &#x00627;&#x00644;&#x00645;&#x00639;&#x00627;&#x00643;&#x00633; &#x00623;&#x00648; &#x00641;&#x0064a; &#x0062d;&#x00627;&#x00644;&#x00629; &#x00627;&#x00644;&#x00645;&#x00634;&#x00627;&#x00631;&#x00643;&#x0064a;&#x00646; &#x00627;&#x00644;&#x00630;&#x0064a;&#x00646; &#x00628;&#x00644;&#x0063a; &#x0062a;&#x00639;&#x0062f;&#x00627;&#x0062f; &#x00627;&#x00644;&#x0062e;&#x00644;&#x00627;&#x0064a;&#x00627; &#x00641;&#x00626;&#x00629; CD4+&#x0200e; &#x00644;&#x0062f;&#x0064a;&#x00647;&#x00645; &#x00623;&#x00642;&#x00644; &#x00645;&#x00646; 200 <bold>&#x000a0; </bold>&#x0062e;&#x00644;&#x0064a;&#x00629;/&#x00645;&#x0064a;&#x00643;&#x00631;&#x00648; &#x00644;&#x0062a;&#x00631; &#x00639;&#x00646;&#x0062f; &#x00628;&#x0062f;&#x00621; ART. &#x00648;&#x0062a;&#x00631;&#x00627;&#x00648;&#x0062d;&#x0062a; &#x0062a;&#x00643;&#x00644;&#x00641;&#x0062a; &#x00625;&#x0062c;&#x00631;&#x00627;&#x00621; &#x0062a;&#x00639;&#x0062f;&#x00627;&#x0062f; &#x00648;&#x00627;&#x0062d;&#x0062f; &#x00644;&#x00644;&#x0062e;&#x00644;&#x00627;&#x0064a;&#x00627; &#x00641;&#x00626;&#x00629; CD4+ &#x00645;&#x00646; 7.37 <bold>&#x000a0; </bold>&#x0062f;&#x00648;&#x00644;&#x00627;&#x00631;&#x0064b;&#x00627; &#x00623;&#x00645;&#x00631;&#x0064a;&#x00643;&#x0064a;&#x0064b;&#x00627; &#x00641;&#x0064a; &#x00627;&#x00644;&#x00623;&#x00631;&#x0062c;&#x00646;&#x0062a;&#x0064a;&#x00646; &#x00625;&#x00644;&#x00649; 64.09 <bold>&#x000a0; </bold>&#x0062f;&#x00648;&#x00644;&#x00627;&#x00631;&#x0064b;&#x00627; &#x00623;&#x00645;&#x00631;&#x0064a;&#x00643;&#x0064a;&#x0064b;&#x00627; &#x00641;&#x0064a; &#x00634;&#x0064a;&#x00644;&#x0064a;&#x0061b; &#x00648;&#x0062a;&#x00631;&#x00627;&#x00648;&#x0062d;&#x0062a; &#x0062a;&#x00643;&#x00644;&#x00641;&#x00629; &#x00627;&#x00644;&#x00645;&#x00631;&#x00629; &#x00627;&#x00644;&#x00648;&#x00627;&#x0062d;&#x0062f;&#x00629; &#x00644;&#x00642;&#x0064a;&#x00627;&#x00633; &#x00627;&#x00644;&#x0062d;&#x00645;&#x00644; &#x00627;&#x00644;&#x00641;&#x0064a;&#x00631;&#x00648;&#x00633;&#x0064a; &#x00645;&#x00646; 20.34 <bold>&#x000a0; </bold>&#x0062f;&#x00648;&#x00644;&#x00627;&#x00631;&#x0064b;&#x00627; &#x00623;&#x00645;&#x00631;&#x0064a;&#x00643;&#x0064a;&#x0064b;&#x00627; &#x00641;&#x0064a; &#x00627;&#x00644;&#x00628;&#x00631;&#x00627;&#x00632;&#x0064a;&#x00644; &#x00625;&#x00644;&#x00649; 186.28 <bold>&#x000a0; </bold>&#x0062f;&#x00648;&#x00644;&#x00627;&#x00631;&#x0064b;&#x00627; &#x00623;&#x00645;&#x00631;&#x0064a;&#x00643;&#x0064a;&#x0064b;&#x00627; &#x00641;&#x0064a; &#x00647;&#x00627;&#x0064a;&#x0062a;&#x0064a;. </p></sec><sec><title>&#x00627;&#x00644;&#x00627;&#x00633;&#x0062a;&#x00646;&#x0062a;&#x00627;&#x0062c; </title><p>&#x0062a;&#x00645; &#x00625;&#x0062c;&#x00631;&#x00627;&#x00621; &#x0062a;&#x00639;&#x0062f;&#x00627;&#x0062f; &#x00627;&#x00644;&#x0062e;&#x00644;&#x00627;&#x0064a;&#x00627; &#x00641;&#x00626;&#x00629; CD4+&#x0200e; &#x00648;&#x00645;&#x00631;&#x00627;&#x00642;&#x00628;&#x00629; &#x00627;&#x00644;&#x0062d;&#x00645;&#x00644; &#x00627;&#x00644;&#x00641;&#x0064a;&#x00631;&#x00648;&#x00633;&#x0064a; &#x00644;&#x00644;&#x00645;&#x00634;&#x00627;&#x00631;&#x00643;&#x0064a;&#x00646; &#x00627;&#x00644;&#x00645;&#x00635;&#x00627;&#x00628;&#x0064a;&#x00646; &#x00628;&#x00639;&#x00648;&#x00632; &#x00627;&#x00644;&#x00645;&#x00646;&#x00627;&#x00639;&#x00629; &#x00627;&#x00644;&#x00628;&#x00634;&#x00631;&#x0064a; &#x00645;&#x00645;&#x00646; &#x0064a;&#x0062a;&#x00644;&#x00642;&#x00648;&#x00646; ART &#x00641;&#x0064a; &#x00627;&#x00644;&#x00645;&#x00646;&#x00637;&#x00642;&#x00629; &#x00627;&#x00644;&#x00645;&#x00634;&#x00627;&#x00631; &#x00625;&#x00644;&#x0064a;&#x00647;&#x00627; &#x00628;&#x00634;&#x00643;&#x00644; &#x00623;&#x00642;&#x00644; &#x0062a;&#x00643;&#x00631;&#x00627;&#x00631;&#x0064b;&#x00627; &#x00641;&#x0064a; &#x00623;&#x0063a;&#x00644;&#x00628; &#x00627;&#x00644;&#x00623;&#x0062d;&#x0064a;&#x00627;&#x00646; &#x00645;&#x00645;&#x00627; &#x00648;&#x00631;&#x0062f; &#x00641;&#x0064a; &#x0062a;&#x00648;&#x00635;&#x0064a;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00645;&#x00628;&#x00627;&#x0062f;&#x00626; &#x00627;&#x00644;&#x0062a;&#x00648;&#x0062c;&#x0064a;&#x00647;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00625;&#x00642;&#x00644;&#x0064a;&#x00645;&#x0064a;&#x00629;. &#x00648;&#x00642;&#x0062f; &#x00627;&#x0062e;&#x0062a;&#x00644;&#x00641;&#x0062a; &#x0062a;&#x00643;&#x00627;&#x00644;&#x0064a;&#x00641; &#x00627;&#x00644;&#x00645;&#x00631;&#x00627;&#x00642;&#x00628;&#x00629; &#x00627;&#x00644;&#x00645;&#x0062e;&#x0062a;&#x00628;&#x00631;&#x0064a;&#x00629; &#x00625;&#x00644;&#x00649; &#x0062d;&#x0062f; &#x00643;&#x00628;&#x0064a;&#x00631;. </p></sec></trans-abstract><trans-abstract xml:lang="zh"><title>&#x06458;&#x08981;</title><sec><title>&#x076ee;&#x07684;</title><p>&#x065e8;&#x05728;&#x0786e;&#x05b9a;&#x05145;&#x05206;&#x076d1;&#x06d4b;&#x07684;&#x0666e;&#x0904d;&#x06027;&#x04ee5;&#x053ca;&#x06d4b;&#x091cf;&#x04e03;&#x04e2a;&#x04e16;&#x0754c;&#x0536b;&#x0751f;&#x07ec4;&#x07ec7;&#x07f8e;&#x06d32;&#x0533a;&#x057df;&#x056fd;&#x05bb6;&#x04e2d;&#x063a5;&#x053d7;&#x06297;&#x09006;&#x08f6c;&#x05f55;&#x075c5;&#x06bd2;&#x06cbb;&#x07597;&#x000a0;(ART)&#x000a0;&#x08005;&#x07684;&#x000a0;CD4+&#x000a0;T&#x000a0;&#x06dcb;&#x05df4;&#x07ec6;&#x080de;&#x0ff08;CD4+&#x000a0;&#x07ec6;&#x080de;&#x0ff09;&#x0548c;&#x04eba;&#x04f53;&#x0514d;&#x075ab;&#x07f3a;&#x0635f;&#x075c5;&#x06bd2;&#x000a0;(HIV)&#x000a0;&#x075c5;&#x06bd2;&#x08f7d;&#x091cf;&#x06240;&#x09700;&#x07684;&#x06210;&#x0672c;&#x03002;</p></sec><sec><title>&#x065b9;&#x06cd5;</title><p>2000&#x000a0;&#x081f3;&#x000a0;2011&#x000a0;&#x05e74;&#x095f4;&#x000a0;14&#x02009;476&#x000a0;&#x0540d;&#x06210;&#x04eba;&#x05728;&#x0963f;&#x06839;&#x05ef7;&#x03001;&#x05df4;&#x0897f;&#x03001;&#x079d8;&#x09c81;&#x03001;&#x06d77;&#x05730;&#x03001;&#x06d2a;&#x090fd;&#x062c9;&#x065af;&#x03001;&#x058a8;&#x0897f;&#x054e5;&#x0548c;&#x0667a;&#x05229;&#x07684;&#x04e03;&#x05bb6;&#x000a0;HIV&#x000a0;&#x08bca;&#x06240;&#x05f00;&#x059cb;&#x04e86;&#x07b2c;&#x04e00;&#x04e2a;&#x000a0;ART&#x000a0;&#x07597;&#x07a0b;&#x0ff0c;&#x06211;&#x04eec;&#x053d6;&#x05f97;&#x04e86;&#x08fd9;&#x04e9b;&#x04eba;&#x07684;&#x056de;&#x06eaf;&#x03001;&#x07eb5;&#x05411;&#x06570;&#x0636e;&#x03002;&#x06211;&#x04eec;&#x04f30;&#x06d4b;&#x04e86;&#x04e3a;&#x0671f;&#x000a0;180&#x000a0;&#x05929;&#x07684;&#x05468;&#x0671f;&#x05728;&#x05145;&#x05206;&#x076d1;&#x06d4b;&#x04e2d;&#x06240;&#x05360;&#x07684;&#x06bd4;&#x04f8b;&#x0ff0c;&#x06211;&#x04eec;&#x089c6;&#x04e4b;&#x04e3a;&#x081f3;&#x05c11;&#x04e00;&#x04e2a;&#x000a0;CD4+&#x000a0;&#x07ec6;&#x080de;&#x08ba1;&#x06570;&#x0548c;&#x04e00;&#x04e2a;&#x075c5;&#x06bd2;&#x08f7d;&#x091cf;&#x03002;&#x000a0;&#x06211;&#x04eec;&#x05229;&#x07528;&#x056de;&#x05f52;&#x06cd5;&#x05206;&#x06790;&#x04e86;&#x04e0e;&#x05145;&#x05206;&#x076d1;&#x06d4b;&#x076f8;&#x05173;&#x07684;&#x056e0;&#x07d20;&#x0ff0c; &#x0540c;&#x065f6;&#x04f30;&#x06d4b;&#x04e86;&#x06d4b;&#x08bd5;&#x07684;&#x06210;&#x0672c;&#x03002;</p></sec><sec><title>&#x07ed3;&#x0679c;</title><p>&#x04e2d;&#x04f4d;&#x0968f;&#x08bbf;&#x0671f;&#x04e3a;&#x000a0;50.4&#x000a0;&#x04e2a;&#x06708;&#x0ff0c;&#x04e3a;&#x0671f;&#x000a0;180&#x000a0;&#x05929;&#x07684;&#x05468;&#x0671f;&#x05728;&#x051c6;&#x0786e;&#x000a0;CD4+&#x000a0;&#x07ec6;&#x080de;&#x08ba1;&#x06570;&#x04e2d;&#x06240;&#x05360;&#x07684;&#x06bd4;&#x04f8b;&#x04e3a;&#x000a0;69%&#x0ff0c;&#x0800c;&#x05728;&#x05145;&#x05206;&#x076d1;&#x06d4b;&#x04e2d;&#x06240;&#x05360;&#x07684;&#x06bd4;&#x04f8b;&#x04e3a;&#x000a0;62%&#x03002; &#x066f4;&#x06709;&#x053ef;&#x080fd;&#x09488;&#x05bf9;&#x08001;&#x05e74;&#x0ff0c;&#x06700;&#x08fd1;&#x05f00;&#x059cb;&#x000a0;ART&#x0ff0c;&#x07b2c;&#x04e00;&#x06b21;&#x07597;&#x07a0b;&#x04f7f;&#x07528;&#x0975e;&#x06838;&#x082f7;&#x09006;&#x08f6c;&#x05f55;&#x09176;&#x06291;&#x05236;&#x05242;&#x06216;&#x05f00;&#x059cb;&#x000a0;ART&#x000a0;&#x065f6;&#x000a0;CD4+&#x000a0;&#x07ec6;&#x080de;&#x08ba1;&#x06570;&#x05c11;&#x04e8e;&#x000a0;200&#x000a0;&#x07ec6;&#x080de;/&#x000b5;l&#x000a0;&#x07684;&#x053c2;&#x04e0e;&#x04eba;&#x05458;&#x05b9e;&#x065bd;&#x05145;&#x05206;&#x076d1;&#x06d4b;&#x03002; &#x04e00;&#x04e2a;&#x000a0;CD4+&#x000a0;&#x07ec6;&#x080de;&#x08ba1;&#x06570;&#x07684;&#x06210;&#x0672c;&#x04ece;&#x0963f;&#x06839;&#x05ef7;&#x000a0;7.37&#x000a0;&#x07f8e;&#x05143;&#x000a0;(US$)&#x000a0;&#x05230;&#x0667a;&#x05229;&#x000a0;64.09&#x000a0;&#x07f8e;&#x05143;&#x000a0;(US$)&#x000a0;&#x04e0d;&#x07b49;&#x0ff1b;&#x04e00;&#x04e2a;&#x075c5;&#x06bd2;&#x08f7d;&#x091cf;&#x07684;&#x06210;&#x0672c;&#x04ece;&#x05df4;&#x0897f;&#x000a0;US$&#x000a0;20.34&#x000a0;&#x07f8e;&#x05143;&#x000a0;(US$)&#x000a0;&#x05230;&#x06d77;&#x05730;&#x000a0;186.28&#x000a0;&#x07f8e;&#x05143;&#x000a0;(US$)&#x000a0;&#x04e0d;&#x07b49;&#x03002;</p></sec><sec><title>&#x07ed3;&#x08bba;</title><p>&#x09488;&#x05bf9;&#x08be5;&#x05730;&#x0533a;&#x063a5;&#x053d7;&#x000a0;ART&#x000a0;&#x06cbb;&#x07597;&#x07684;&#x000a0;HIV&#x000a0;&#x0611f;&#x067d3;&#x08005;&#x053c2;&#x04e0e;&#x04eba;&#x05458;&#x0ff0c;&#x05c55;&#x05f00;&#x000a0;CD4+&#x000a0;&#x07ec6;&#x080de;&#x08ba1;&#x06570;&#x0548c;&#x075c5;&#x06bd2;&#x08f7d;&#x091cf;&#x076d1;&#x06d4b;&#x07684;&#x06b21;&#x06570;&#x0901a;&#x05e38;&#x05c11;&#x04e8e;&#x05730;&#x0533a;&#x06307;&#x05bfc;&#x065b9;&#x09488;&#x06240;&#x05efa;&#x08bae;&#x07684;&#x06b21;&#x06570;&#x03002; &#x076d1;&#x06d4b;&#x07684;&#x05b9e;&#x09a8c;&#x05ba4;&#x06210;&#x0672c;&#x05dee;&#x05f02;&#x05f88;&#x05927;&#x03002;</p></sec></trans-abstract><trans-abstract xml:lang="ru"><title>&#x00420;&#x00435;&#x00437;&#x0044e;&#x0043c;&#x00435;</title><sec><title>&#x00426;&#x00435;&#x0043b;&#x0044c;</title><p>&#x0041e;&#x00446;&#x00435;&#x0043d;&#x00438;&#x00442;&#x0044c; &#x0043d;&#x00430;&#x0043b;&#x00438;&#x00447;&#x00438;&#x00435; &#x0043d;&#x00430;&#x00434;&#x0043b;&#x00435;&#x00436;&#x00430;&#x00449;&#x00435;&#x00433;&#x0043e; &#x0043d;&#x00430;&#x00431;&#x0043b;&#x0044e;&#x00434;&#x00435;&#x0043d;&#x00438;&#x0044f;, &#x00430; &#x00442;&#x00430;&#x0043a;&#x00436;&#x00435; &#x00441;&#x00442;&#x0043e;&#x00438;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x0044c; &#x00430;&#x0043d;&#x00430;&#x0043b;&#x00438;&#x00437;&#x00430; &#x0043a;&#x0043e;&#x0043b;&#x00438;&#x00447;&#x00435;&#x00441;&#x00442;&#x00432;&#x00430; T-&#x0043b;&#x00438;&#x0043c;&#x00444;&#x0043e;&#x00446;&#x00438;&#x00442;&#x0043e;&#x00432;&#x000a0;CD4+ (&#x0043a;&#x0043b;&#x00435;&#x00442;&#x0043e;&#x0043a;&#x000a0;CD4+) &#x00438; &#x0043a;&#x0043e;&#x0043d;&#x00446;&#x00435;&#x0043d;&#x00442;&#x00440;&#x00430;&#x00446;&#x00438;&#x00438; &#x00432;&#x00438;&#x00440;&#x00443;&#x00441;&#x00430; &#x00438;&#x0043c;&#x0043c;&#x00443;&#x0043d;&#x0043e;&#x00434;&#x00435;&#x00444;&#x00438;&#x00446;&#x00438;&#x00442;&#x00430; &#x00447;&#x00435;&#x0043b;&#x0043e;&#x00432;&#x00435;&#x0043a;&#x00430;&#x000a0;(&#x00412;&#x00418;&#x00427;) &#x00432; &#x0043a;&#x00440;&#x0043e;&#x00432;&#x00438; &#x00443; &#x0043f;&#x00430;&#x00446;&#x00438;&#x00435;&#x0043d;&#x00442;&#x0043e;&#x00432;, &#x0043f;&#x0043e;&#x0043b;&#x00443;&#x00447;&#x00430;&#x0044e;&#x00449;&#x00438;&#x00445; &#x00430;&#x0043d;&#x00442;&#x00438;&#x00440;&#x00435;&#x00442;&#x00440;&#x0043e;&#x00432;&#x00438;&#x00440;&#x00443;&#x00441;&#x0043d;&#x00443;&#x0044e; &#x00442;&#x00435;&#x00440;&#x00430;&#x0043f;&#x00438;&#x0044e;&#x000a0;(&#x00410;&#x00420;&#x00412;&#x00422;) &#x00432; &#x00441;&#x00435;&#x0043c;&#x00438; &#x00441;&#x00442;&#x00440;&#x00430;&#x0043d;&#x00430;&#x00445; &#x00430;&#x0043c;&#x00435;&#x00440;&#x00438;&#x0043a;&#x00430;&#x0043d;&#x00441;&#x0043a;&#x0043e;&#x00433;&#x0043e; &#x00440;&#x00435;&#x00433;&#x00438;&#x0043e;&#x0043d;&#x00430;&#x000a0;&#x00412;&#x0041e;&#x00417;.</p></sec><sec><title>&#x0041c;&#x00435;&#x00442;&#x0043e;&#x00434;&#x0044b;</title><p>&#x00411;&#x0044b;&#x0043b;&#x00438; &#x00441;&#x0043e;&#x00431;&#x00440;&#x00430;&#x0043d;&#x0044b; &#x00434;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x00435; &#x00440;&#x00435;&#x00442;&#x00440;&#x0043e;&#x00441;&#x0043f;&#x00435;&#x0043a;&#x00442;&#x00438;&#x00432;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x00434;&#x0043e;&#x0043b;&#x00433;&#x0043e;&#x00441;&#x00440;&#x0043e;&#x00447;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f; 14&#x000a0;476&#x000a0;&#x00432;&#x00437;&#x00440;&#x0043e;&#x00441;&#x0043b;&#x0044b;&#x00445; &#x0043f;&#x00430;&#x00446;&#x00438;&#x00435;&#x0043d;&#x00442;&#x0043e;&#x00432;, &#x00432;&#x0043f;&#x00435;&#x00440;&#x00432;&#x0044b;&#x00435; &#x0043d;&#x00430;&#x00447;&#x00430;&#x00432;&#x00448;&#x00438;&#x00445; &#x0043f;&#x0043e;&#x0043b;&#x00443;&#x00447;&#x00430;&#x00442;&#x0044c;&#x000a0;&#x00410;&#x00420;&#x00412;&#x00422; &#x00432; &#x00441;&#x00435;&#x0043c;&#x00438; &#x0043a;&#x0043b;&#x00438;&#x0043d;&#x00438;&#x0043a;&#x00430;&#x00445; &#x0043f;&#x0043e; &#x0043b;&#x00435;&#x00447;&#x00435;&#x0043d;&#x00438;&#x0044e;&#x000a0;&#x00412;&#x00418;&#x00427; &#x00432; &#x00410;&#x00440;&#x00433;&#x00435;&#x0043d;&#x00442;&#x00438;&#x0043d;&#x00435;, &#x00411;&#x00440;&#x00430;&#x00437;&#x00438;&#x0043b;&#x00438;&#x00438;, &#x00413;&#x00430;&#x00438;&#x00442;&#x00438;, &#x00413;&#x0043e;&#x0043d;&#x00434;&#x00443;&#x00440;&#x00430;&#x00441;&#x00435;, &#x0041c;&#x00435;&#x0043a;&#x00441;&#x00438;&#x0043a;&#x00435;, &#x0041f;&#x00435;&#x00440;&#x00443; &#x00438; &#x00427;&#x00438;&#x0043b;&#x00438; &#x00432; &#x0043f;&#x00435;&#x00440;&#x00438;&#x0043e;&#x00434; &#x00441; 2000&#x000a0;&#x0043f;&#x0043e; 2011&#x000a0;&#x00433;. &#x0041e;&#x00446;&#x00435;&#x0043d;&#x00438;&#x00432;&#x00430;&#x0043b;&#x00430;&#x00441;&#x0044c; &#x00434;&#x0043e;&#x0043b;&#x0044f; 180-&#x00434;&#x0043d;&#x00435;&#x00432;&#x0043d;&#x0044b;&#x00445; &#x0043f;&#x00435;&#x00440;&#x00438;&#x0043e;&#x00434;&#x0043e;&#x00432; &#x00441; &#x0043d;&#x00430;&#x00434;&#x0043b;&#x00435;&#x00436;&#x00430;&#x00449;&#x00438;&#x0043c; &#x0043d;&#x00430;&#x00431;&#x0043b;&#x0044e;&#x00434;&#x00435;&#x0043d;&#x00438;&#x00435;&#x0043c;, &#x0043f;&#x0043e;&#x00434;&#x00440;&#x00430;&#x00437;&#x00443;&#x0043c;&#x00435;&#x00432;&#x00430;&#x0044e;&#x00449;&#x00438;&#x0043c; &#x0043a;&#x00430;&#x0043a; &#x0043c;&#x00438;&#x0043d;&#x00438;&#x0043c;&#x00443;&#x0043c; &#x0043e;&#x00434;&#x00438;&#x0043d; &#x00430;&#x0043d;&#x00430;&#x0043b;&#x00438;&#x00437; &#x0043d;&#x00430; &#x0043a;&#x0043e;&#x0043b;&#x00438;&#x00447;&#x00435;&#x00441;&#x00442;&#x00432;&#x0043e; &#x0043a;&#x0043b;&#x00435;&#x00442;&#x0043e;&#x0043a;&#x000a0;CD4+ &#x00438; &#x0043e;&#x00434;&#x0043d;&#x0043e; &#x00438;&#x00437;&#x0043c;&#x00435;&#x00440;&#x00435;&#x0043d;&#x00438;&#x00435; &#x0043a;&#x0043e;&#x0043d;&#x00446;&#x00435;&#x0043d;&#x00442;&#x00440;&#x00430;&#x00446;&#x00438;&#x00438; &#x00432;&#x00438;&#x00440;&#x00443;&#x00441;&#x00430;. &#x00424;&#x00430;&#x0043a;&#x00442;&#x0043e;&#x00440;&#x0044b;, &#x00441;&#x00432;&#x0044f;&#x00437;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x00435; &#x00441; &#x0043d;&#x00430;&#x00434;&#x0043b;&#x00435;&#x00436;&#x00430;&#x00449;&#x00438;&#x0043c; &#x0043d;&#x00430;&#x00431;&#x0043b;&#x0044e;&#x00434;&#x00435;&#x0043d;&#x00438;&#x00435;&#x0043c; &#x00437;&#x00430; &#x0043f;&#x00430;&#x00446;&#x00438;&#x00435;&#x0043d;&#x00442;&#x00430;&#x0043c;&#x00438;, &#x00430;&#x0043d;&#x00430;&#x0043b;&#x00438;&#x00437;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043b;&#x00438;&#x00441;&#x0044c; &#x00441; &#x00438;&#x00441;&#x0043f;&#x0043e;&#x0043b;&#x0044c;&#x00437;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00435;&#x0043c; &#x00440;&#x00435;&#x00433;&#x00440;&#x00435;&#x00441;&#x00441;&#x00438;&#x0043e;&#x0043d;&#x0043d;&#x0044b;&#x00445; &#x0043c;&#x00435;&#x00442;&#x0043e;&#x00434;&#x0043e;&#x00432;. &#x00411;&#x0044b;&#x0043b;&#x00430; &#x0043f;&#x00440;&#x0043e;&#x00432;&#x00435;&#x00434;&#x00435;&#x0043d;&#x00430; &#x0043e;&#x00446;&#x00435;&#x0043d;&#x0043a;&#x00430; &#x00441;&#x00442;&#x0043e;&#x00438;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x00438; &#x00430;&#x0043d;&#x00430;&#x0043b;&#x00438;&#x00437;&#x0043e;&#x00432;.</p></sec><sec><title>&#x00420;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x0044b;</title><p>&#x00421;&#x00440;&#x00435;&#x00434;&#x0043d;&#x00435;&#x00435; &#x00432;&#x00440;&#x00435;&#x0043c;&#x0044f; &#x0043f;&#x0043e;&#x00441;&#x0043b;&#x00435;&#x00434;&#x00443;&#x0044e;&#x00449;&#x00435;&#x00433;&#x0043e; &#x00432;&#x00440;&#x00430;&#x00447;&#x00435;&#x00431;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x0043d;&#x00430;&#x00431;&#x0043b;&#x0044e;&#x00434;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00441;&#x0043e;&#x00441;&#x00442;&#x00430;&#x00432;&#x0043b;&#x0044f;&#x0043b;&#x0043e; 50,4&#x000a0;&#x0043c;&#x00435;&#x00441;&#x0044f;&#x00446;&#x00430;. &#x00414;&#x0043e;&#x0043b;&#x0044f; 180-&#x00434;&#x0043d;&#x00435;&#x00432;&#x0043d;&#x0044b;&#x00445; &#x0043f;&#x00435;&#x00440;&#x00438;&#x0043e;&#x00434;&#x0043e;&#x00432; &#x00430;&#x00434;&#x00435;&#x0043a;&#x00432;&#x00430;&#x00442;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x0043c;&#x0043e;&#x0043d;&#x00438;&#x00442;&#x0043e;&#x00440;&#x00438;&#x0043d;&#x00433;&#x00430; &#x00447;&#x00438;&#x00441;&#x0043b;&#x00430; &#x0043b;&#x00438;&#x0043c;&#x00444;&#x0043e;&#x00446;&#x00438;&#x00442;&#x0043e;&#x00432; CD4+ &#x00441;&#x0043e;&#x00441;&#x00442;&#x00430;&#x00432;&#x00438;&#x0043b;&#x00430; 69%, &#x00432; &#x00442;&#x0043e; &#x00432;&#x00440;&#x00435;&#x0043c;&#x0044f; &#x0043a;&#x00430;&#x0043a; &#x00434;&#x0043e;&#x0043b;&#x0044f; &#x0043d;&#x00430;&#x00434;&#x0043b;&#x00435;&#x00436;&#x00430;&#x00449;&#x00435;&#x00433;&#x0043e; &#x0043d;&#x00430;&#x00431;&#x0043b;&#x0044e;&#x00434;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00441;&#x0043e;&#x00441;&#x00442;&#x00430;&#x00432;&#x00438;&#x0043b;&#x00430; 62%. &#x0041d;&#x00430;&#x00438;&#x00431;&#x0043e;&#x0043b;&#x0044c;&#x00448;&#x00430;&#x0044f; &#x00432;&#x00435;&#x00440;&#x0043e;&#x0044f;&#x00442;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x0044c; &#x0043d;&#x00430;&#x00434;&#x0043b;&#x00435;&#x00436;&#x00430;&#x00449;&#x00435;&#x00433;&#x0043e; &#x0043d;&#x00430;&#x00431;&#x0043b;&#x0044e;&#x00434;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00431;&#x0044b;&#x0043b;&#x00430; &#x00432;&#x0044b;&#x0044f;&#x00432;&#x0043b;&#x00435;&#x0043d;&#x00430; &#x00441;&#x00440;&#x00435;&#x00434;&#x00438; &#x00443;&#x00447;&#x00430;&#x00441;&#x00442;&#x0043d;&#x00438;&#x0043a;&#x0043e;&#x00432; &#x00441;&#x00442;&#x00430;&#x00440;&#x00448;&#x00435;&#x00433;&#x0043e; &#x00432;&#x0043e;&#x00437;&#x00440;&#x00430;&#x00441;&#x00442;&#x00430;. &#x0042d;&#x00442;&#x00438; &#x0043f;&#x00430;&#x00446;&#x00438;&#x00435;&#x0043d;&#x00442;&#x0044b; &#x0043d;&#x00430;&#x00447;&#x00430;&#x0043b;&#x00438; &#x00410;&#x00420;&#x00412;&#x00422;&#x000a0;&#x0043d;&#x00435;&#x00434;&#x00430;&#x00432;&#x0043d;&#x0043e;, &#x0043b;&#x00438;&#x00431;&#x0043e; &#x00438;&#x00445; &#x0043f;&#x00435;&#x00440;&#x00432;&#x0044b;&#x00439; &#x0043a;&#x00443;&#x00440;&#x00441; &#x0043b;&#x00435;&#x00447;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00432;&#x0043a;&#x0043b;&#x0044e;&#x00447;&#x00430;&#x0043b; &#x0043f;&#x00440;&#x00438;&#x00435;&#x0043c; &#x0043d;&#x00435;&#x0043d;&#x00443;&#x0043a;&#x0043b;&#x00435;&#x0043e;&#x00437;&#x00438;&#x00434;&#x0043d;&#x0044b;&#x00445; &#x00438;&#x0043d;&#x00433;&#x00438;&#x00431;&#x00438;&#x00442;&#x0043e;&#x00440;&#x0043e;&#x00432; &#x0043e;&#x00431;&#x00440;&#x00430;&#x00442;&#x0043d;&#x0043e;&#x00439; &#x00442;&#x00440;&#x00430;&#x0043d;&#x00441;&#x0043a;&#x00440;&#x00438;&#x0043f;&#x00442;&#x00430;&#x00437;&#x0044b;, &#x0043b;&#x00438;&#x00431;&#x0043e; &#x00447;&#x00438;&#x00441;&#x0043b;&#x0043e; &#x0043a;&#x0043b;&#x00435;&#x00442;&#x0043e;&#x0043a;&#x000a0;CD4+ &#x00443; &#x0044d;&#x00442;&#x00438;&#x00445; &#x0043f;&#x00430;&#x00446;&#x00438;&#x00435;&#x0043d;&#x00442;&#x0043e;&#x00432; &#x00441;&#x0043e;&#x00441;&#x00442;&#x00430;&#x00432;&#x0043b;&#x0044f;&#x0043b;&#x0043e; &#x0043c;&#x00435;&#x0043d;&#x00435;&#x00435; 200&#x000a0;&#x0043a;&#x0043b;&#x00435;&#x00442;&#x0043e;&#x0043a;/&#x0043c;&#x0043a;&#x0043b; &#x00432; &#x0043d;&#x00430;&#x00447;&#x00430;&#x0043b;&#x00435;&#x000a0;&#x00410;&#x00420;&#x00412;&#x00422;. &#x00421;&#x00442;&#x0043e;&#x00438;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x0044c; &#x0043e;&#x00434;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x00430;&#x0043d;&#x00430;&#x0043b;&#x00438;&#x00437;&#x00430; &#x00434;&#x0043b;&#x0044f; &#x0043e;&#x0043f;&#x00440;&#x00435;&#x00434;&#x00435;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00447;&#x00438;&#x00441;&#x0043b;&#x00430; &#x0043a;&#x0043b;&#x00435;&#x00442;&#x0043e;&#x0043a;&#x000a0;CD4+ &#x00432;&#x00430;&#x00440;&#x0044c;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043b;&#x00430;&#x00441;&#x0044c; &#x0043e;&#x00442; 7,37&#x000a0;&#x00434;&#x0043e;&#x0043b;&#x0043b;.&#x000a0;&#x00421;&#x00428;&#x00410; &#x00432; &#x00410;&#x00440;&#x00433;&#x00435;&#x0043d;&#x00442;&#x00438;&#x0043d;&#x00435; &#x00434;&#x0043e; 64,09&#x000a0;&#x00434;&#x0043e;&#x0043b;&#x0043b;.&#x000a0;&#x00421;&#x00428;&#x00410; &#x00432; &#x00427;&#x00438;&#x0043b;&#x00438;. &#x00421;&#x00442;&#x0043e;&#x00438;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x0044c; &#x0043e;&#x00434;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x00438;&#x00437;&#x0043c;&#x00435;&#x00440;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00441;&#x0043e;&#x00434;&#x00435;&#x00440;&#x00436;&#x00430;&#x0043d;&#x00438;&#x0044f; &#x00432;&#x00438;&#x00440;&#x00443;&#x00441;&#x00430; &#x00432; &#x0043a;&#x00440;&#x0043e;&#x00432;&#x00438; &#x00432;&#x00430;&#x00440;&#x0044c;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043b;&#x00430;&#x00441;&#x0044c; &#x0043e;&#x00442; 20,34&#x000a0;&#x00434;&#x0043e;&#x0043b;&#x0043b;.&#x000a0;&#x00421;&#x00428;&#x00410; &#x00432; &#x00411;&#x00440;&#x00430;&#x00437;&#x00438;&#x0043b;&#x00438;&#x00438; &#x00434;&#x0043e; 186,28&#x000a0;&#x00434;&#x0043e;&#x0043b;&#x0043b;.&#x000a0;&#x00421;&#x00428;&#x00410; &#x0043d;&#x00430; &#x00413;&#x00430;&#x00438;&#x00442;&#x00438;.</p></sec><sec><title>&#x00412;&#x0044b;&#x00432;&#x0043e;&#x00434;</title><p>&#x00423; &#x00412;&#x00418;&#x00427;-&#x00438;&#x0043d;&#x00444;&#x00438;&#x00446;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x00445; &#x00443;&#x00447;&#x00430;&#x00441;&#x00442;&#x0043d;&#x00438;&#x0043a;&#x0043e;&#x00432; &#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f;, &#x0043f;&#x0043e;&#x0043b;&#x00443;&#x00447;&#x00430;&#x0044e;&#x00449;&#x00438;&#x00445;&#x000a0;&#x00410;&#x00420;&#x00412;&#x00422; &#x00432; &#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x00443;&#x00435;&#x0043c;&#x0043e;&#x0043c; &#x00440;&#x00435;&#x00433;&#x00438;&#x0043e;&#x0043d;&#x00435;, &#x0043c;&#x0043e;&#x0043d;&#x00438;&#x00442;&#x0043e;&#x00440;&#x00438;&#x0043d;&#x00433; &#x00447;&#x00438;&#x00441;&#x0043b;&#x00430; &#x0043a;&#x0043b;&#x00435;&#x00442;&#x0043e;&#x0043a;&#x000a0;CD4+ &#x00438; &#x00441;&#x0043e;&#x00434;&#x00435;&#x00440;&#x00436;&#x00430;&#x0043d;&#x00438;&#x0044f; &#x00432;&#x00438;&#x00440;&#x00443;&#x00441;&#x00430; &#x00432; &#x0043a;&#x00440;&#x0043e;&#x00432;&#x00438; &#x0043e;&#x00441;&#x00443;&#x00449;&#x00435;&#x00441;&#x00442;&#x00432;&#x0043b;&#x0044f;&#x0043b;&#x00441;&#x0044f; &#x00440;&#x00435;&#x00436;&#x00435;, &#x00447;&#x00435;&#x0043c; &#x0043f;&#x00440;&#x00435;&#x00434;&#x0043f;&#x00438;&#x00441;&#x0044b;&#x00432;&#x00430;&#x0044e;&#x00442; &#x00440;&#x00435;&#x0043a;&#x0043e;&#x0043c;&#x00435;&#x0043d;&#x00434;&#x00430;&#x00446;&#x00438;&#x00438; &#x0043f;&#x0043e; &#x00434;&#x00430;&#x0043d;&#x0043d;&#x0043e;&#x0043c;&#x00443; &#x00440;&#x00435;&#x00433;&#x00438;&#x0043e;&#x0043d;&#x00443;. &#x00421;&#x00442;&#x0043e;&#x00438;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x0044c; &#x00440;&#x00430;&#x00441;&#x00445;&#x0043e;&#x00434;&#x0043e;&#x00432; &#x0043d;&#x00430; &#x0043b;&#x00430;&#x00431;&#x0043e;&#x00440;&#x00430;&#x00442;&#x0043e;&#x00440;&#x0043d;&#x0044b;&#x00435; &#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f; &#x00437;&#x0043d;&#x00430;&#x00447;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0043e; &#x00440;&#x00430;&#x00437;&#x0043b;&#x00438;&#x00447;&#x00430;&#x0043b;&#x00430;&#x00441;&#x0044c; &#x0043c;&#x00435;&#x00436;&#x00434;&#x00443; &#x00441;&#x00442;&#x00440;&#x00430;&#x0043d;&#x00430;&#x0043c;&#x00438;.</p></sec></trans-abstract></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>For people living with human immunodeficiency virus (HIV) who are receiving combination antiretroviral therapy (ART), the most important predictors of treatment outcomes are CD4+ T-lymphocyte (CD4+ cell) count and HIV load in the blood.<xref rid="R1" ref-type="bibr">1</xref> Both international and national health organizations recommend that the CD4+ cell count, viral load or both be measured routinely every three to 12&#x000a0;months during ART.<xref rid="R2" ref-type="bibr">2</xref>&#x02013;<xref rid="R4" ref-type="bibr">4</xref> In Latin America, national clinical guidelines recommend measuring the CD4+ cell count and the viral load every two to six&#x000a0;months in people starting ART and then every three to six&#x000a0;months once viral suppression has been achieved.<xref rid="R5" ref-type="bibr">5</xref>&#x02013;<xref rid="R10" ref-type="bibr">10</xref> Recently, the World Health Organization (WHO) updated its guidelines to promote earlier treatment initiation and enhanced monitoring, preferably by viral load testing.<xref rid="R2" ref-type="bibr">2</xref></p><p>The number of people receiving ART and the cost of treatment are expected to increase in the future because of the worldwide trend to initiate ART at higher CD4+ cell counts and earlier identification of HIV-infected individuals. Improvements in life expectancy resulting from expanded ART programmes are also thought to increase costs.<xref rid="R11" ref-type="bibr">11</xref> WHO has been working with regional United Nations agencies and in-country staff and with national ministries of health to support the development and implementation of ART guidelines in individual countries.<xref rid="R12" ref-type="bibr">12</xref> At present, however, there is little information on the application of, and adherence to, current WHO and national clinical guidelines in the WHO Region of the Americas. The aims of this study were to determine how frequently the CD4+ cell count and HIV viral load were monitored in people receiving ART in the region between 2000 and 2011. We also wanted to assess the level of adherence to local clinical guidelines and to identify factors associated with infrequent CD4+ cell count and viral load monitoring. We also estimated the cost of CD4+ cell count and viral load measurements in the region.</p></sec><sec sec-type="methods"><title>Methods</title><p>We used retrospective, longitudinal data routinely collected during clinical care and held by the Caribbean, Central and South America Network for HIV Epidemiology (CCASAnet),<xref rid="R13" ref-type="bibr">13</xref> which comprises a consortium of adult HIV clinics from seven countries (Argentina, Brazil, Chile, Haiti, Honduras, Mexico and Peru). CCASAnet was established in 2006;<xref rid="R14" ref-type="bibr">14</xref> the consortium sites that contributed data to this study are listed in <xref ref-type="boxed-text" rid="B1">Box&#x000a0;1</xref>. All participants who were at least 18&#x000a0;years of age and who initiated their first ART regimen between 1&#x000a0;January 2000 and 31&#x000a0;December 2011 were eligible for inclusion. We excluded participants enrolled in clinical trials to avoid potential bias due to special monitoring practices in these trials.</p><boxed-text id="B1" position="float" orientation="portrait"><label>Box&#x000a0;1</label><caption><title>Participating adult HIV clinic sites from the Caribbean, Central and South America Network for HIV Epidemiology</title></caption><p>Fundaci&#x000f3;n Hu&#x000e9;sped, Buenos Aires, Argentina.</p><p>Instituto de Pesquisa Clinica Evandro Chagas, Fundac&#x000e3;o Oswaldo Cruz, Rio de Janeiro, Brazil.</p><p>Fundaci&#x000f3;n Arriar&#x000e1;n, Santiago, Chile.</p><p>Le Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes, Port-au-Prince, Haiti.</p><p>Instituto Hondure&#x000f1;o de Seguridad Social and Hospital Escuela, Tegucigalpa, Honduras.</p><p>Instituto Nacional de Ciencias M&#x000e9;dicas y Nutrici&#x000f3;n Salvador Zubir&#x000e1;n, Mexico City, Mexico.</p><p>Instituto de Medicina Tropical Alexander von Humboldt, Lima, Peru.</p></boxed-text><p>The follow-up period after ART initiation was divided into 180-day periods; follow-up ended on the day of the last recorded visit or when death occurred. Participants were defined as being lost to follow-up if they had not visited the clinic in the 12&#x000a0;months before the database closing date of 1&#x000a0;January 2012. For the primary analysis, treatment monitoring was defined as adequate if at least one CD4+ cell count and one viral load measurement had been made in each 180-day follow-up period. The site in Haiti did not measure viral load during the study period and was not included in the primary analysis. However, the Haitian site was included in a secondary analysis, in which we defined adequate monitoring using the CD4+ cell count alone (in which case, at least one CD4+ cell count had to be measured during each 180-day period).</p><p>The primary study outcome was the proportion of 180-day periods during which there was adequate monitoring. Any remaining follow-up time that did not fit within a 180-day period was ignored. For example, if a participant was followed for 400&#x000a0;days, two 180-day periods were included in calculating the proportion of follow-up with adequate monitoring; the remaining 40&#x000a0;days were not included. However, the remaining follow-up periods were included in sensitivity analyses as additional periods. The CD4+ cell count at ART initiation was defined as the measurement closest to the start of ART, but no more than 180&#x000a0;days before or 7&#x000a0;days after the start, and was categorized as either less than 200, 200&#x02013;350 or more than 350&#x000a0;cells/&#x000b5;L. A participant was described as having had an AIDS-defining event before ART initiation if they had clinical disease that could be classified as Centers for Disease Control and Prevention category C or WHO stage IV. Combination antiretroviral therapy was defined as: (i)&#x000a0;therapy based on a non-nucleoside reverse transcriptase inhibitor (e.g. one non-nucleoside reverse transcriptase inhibitor plus two nucleoside reverse transcriptase inhibitors); (ii)&#x000a0;protease inhibitor-based therapy, including treatment with one ritonavir-boosted or unboosted protease inhibitor plus two nucleoside reverse transcriptase inhibitors; (iii)&#x000a0;triple nucleoside reverse transcriptase inhibitor regimens; or (iv)&#x000a0;any other regimen containing at least three drugs. Data were collected at each study site and entered into the database at the local level using codes that did not identify individual participants. Thereafter, data were sent for harmonization to the CCASAnet data coordinating centre at Vanderbilt University, Nashville, United States of America. The coordinating centre also carried out data quality checks and on-site audits to ensure data accuracy. Ethical approval was obtained from institutional review boards at each study site and at Vanderbilt University.</p><sec><title>Statistical analysis</title><p>Participant-level factors associated with the frequency of monitoring were identified using Poisson regression: the number of 180-day periods with adequate monitoring was the outcome and the total number of 180-day periods was the offset. A quasi-Poisson estimation procedure was used. Multivariable models included age, sex, CD4+ cell count at ART initiation, year of ART initiation, prior AIDS-defining events and the first ART regimen. Missing data on the CD4+ cell count and prior AIDS-defining events were imputed using multiple imputation with 10 replications. The rate ratio for adequate monitoring was computed for each site and the combined rate ratio across all sites was estimated using random effects meta-analysis. The costs of measuring the CD4+ cell count and viral load were obtained for each site in 2014 in the local currency. Costs were subsequently converted to United States dollars (US$) using exchange rates from the <italic>Wall Street Journal</italic> for Argentina, Brazil, Chile, Mexico and Peru<xref rid="R15" ref-type="bibr">15</xref> and rates from local central banks for Haiti<xref rid="R16" ref-type="bibr">16</xref> and Honduras.<xref rid="R17" ref-type="bibr">17</xref> The median cost of all CD4+ cell counts and viral load measurements per participant per year were estimated for each site. All analyses were performed using R statistical software (R-foundation, Vienna, Austria). Analysis scripts are available from the corresponding author.</p></sec></sec><sec sec-type="results"><title>Results</title><p>A total of 14&#x02009;476 participants at the study sites met inclusion criteria: 1285 from Argentina, 2446 from Brazil, 1080 from Chile, 5696 from Haiti, 789 from Honduras, 772 from Mexico and 2408 from Peru. The characteristics of the sites, their sources of funding and the approximate cost of laboratory measurements at each site are summarized in <xref ref-type="table" rid="T1">Table&#x000a0;1</xref>. The cost of a CD4+ cell count measurement at the different sites ranged from US$&#x000a0;7.37 in Argentina to US$&#x000a0;64.09 in Chile and the cost of a viral load measurement ranged from US$&#x000a0;20.34 in Brazil to US$&#x000a0;186.28 in Haiti. Guidelines used by all sites recommended measuring the CD4+ cell count every six&#x000a0;months or more frequently. <xref ref-type="table" rid="T2">Table&#x000a0;2</xref> lists the participants&#x02019; demographic characteristics at ART initiation at each site. The median follow-up time was 50.4&#x000a0;months (interquartile range, IQR: 27&#x02013;82). Overall loss to follow-up was 709&#x000a0;participants (4.9%) ranging from 5% or less in Brazil and Peru to 24.7% in Argentina. The Haitian site provided data only for participants who were not lost to follow-up. There were 967 deaths (6.7%).</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Antiretroviral treatment programmes in seven countries in the WHO Region of the Americas, 2000&#x02013;2011</title></caption><table frame="hsides" rules="groups"><col width="111" span="1"/><col width="91" span="1"/><col width="77" span="1"/><col width="77" span="1"/><col width="67" span="1"/><col width="84" span="1"/><col width="78" span="1"/><col width="78" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Characteristic</th><th colspan="7" valign="top" align="center" scope="colgroup" rowspan="1">Site of adult HIV clinic<sup>a</sup><hr/></th></tr><tr><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">Argentina</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Brazil</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Chile</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Haiti</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Honduras</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Mexico</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Peru</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">No. of participants in study</td><td valign="top" align="center" rowspan="1" colspan="1">1285</td><td valign="top" align="center" rowspan="1" colspan="1">2446</td><td valign="top" align="center" rowspan="1" colspan="1">1080</td><td valign="top" align="center" rowspan="1" colspan="1">5696</td><td valign="top" align="center" rowspan="1" colspan="1">789</td><td valign="top" align="center" rowspan="1" colspan="1">772</td><td valign="top" align="center" rowspan="1" colspan="1">2408</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Start of universal access to ART, year</td><td valign="top" align="center" rowspan="1" colspan="1">2000</td><td valign="top" align="center" rowspan="1" colspan="1">1991<sup>b</sup></td><td valign="top" align="center" rowspan="1" colspan="1">2003</td><td valign="top" align="center" rowspan="1" colspan="1">2003</td><td valign="top" align="center" rowspan="1" colspan="1">2003</td><td valign="top" align="center" rowspan="1" colspan="1">2002</td><td valign="top" align="center" rowspan="1" colspan="1">2004</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Type of clinic</td><td valign="top" align="center" rowspan="1" colspan="1">Private</td><td valign="top" align="center" rowspan="1" colspan="1">Public</td><td valign="top" align="center" rowspan="1" colspan="1">Public</td><td valign="top" align="center" rowspan="1" colspan="1">NGO</td><td valign="top" align="center" rowspan="1" colspan="1">Public</td><td valign="top" align="center" rowspan="1" colspan="1">Public</td><td valign="top" align="center" rowspan="1" colspan="1">Public</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Guidelines used for monitoring ART efficacy</td><td valign="top" align="center" rowspan="1" colspan="1">SADI, MOH</td><td valign="top" align="center" rowspan="1" colspan="1">MOH</td><td valign="top" align="center" rowspan="1" colspan="1">MOH</td><td valign="top" align="center" rowspan="1" colspan="1">MOH, PAHO</td><td valign="top" align="center" rowspan="1" colspan="1">MOH</td><td valign="top" align="center" rowspan="1" colspan="1">MOH</td><td valign="top" align="center" rowspan="1" colspan="1">MOH</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Recommended periodicity of CD4+ cell count monitoring</td><td valign="top" align="center" rowspan="1" colspan="1">3&#x02013;4&#x000a0;months</td><td valign="top" align="center" rowspan="1" colspan="1">3&#x02013;6&#x000a0;months</td><td valign="top" align="center" rowspan="1" colspan="1">3&#x02013;4&#x000a0;months<sup>c</sup></td><td valign="top" align="center" rowspan="1" colspan="1">6&#x000a0;months</td><td valign="top" align="center" rowspan="1" colspan="1">6&#x000a0;months</td><td valign="top" align="center" rowspan="1" colspan="1">4&#x02013;6&#x000a0;months</td><td valign="top" align="center" rowspan="1" colspan="1">6&#x000a0;months</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Cost of one CD4+ cell count, US$<sup>d</sup></td><td valign="top" align="center" rowspan="1" colspan="1">7.37</td><td valign="top" align="center" rowspan="1" colspan="1">17.62</td><td valign="top" align="center" rowspan="1" colspan="1">64.09</td><td valign="top" align="center" rowspan="1" colspan="1">32.6</td><td valign="top" align="center" rowspan="1" colspan="1">14.31<break/>33.39</td><td valign="top" align="center" rowspan="1" colspan="1">59.67</td><td valign="top" align="center" rowspan="1" colspan="1">38.12<sup>e</sup></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Source of funding for CD4+ cell count monitoring</td><td valign="top" align="center" rowspan="1" colspan="1">Refund from Argentine government, social insurance</td><td valign="top" align="center" rowspan="1" colspan="1">Brazilian government</td><td valign="top" align="center" rowspan="1" colspan="1">Chilean government</td><td valign="top" align="center" rowspan="1" colspan="1">PEPFAR, GFATM</td><td valign="top" align="center" rowspan="1" colspan="1">Honduran government, social insurance</td><td valign="top" align="center" rowspan="1" colspan="1">Mexican government</td><td valign="top" align="center" rowspan="1" colspan="1">Peruvian government</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Cost of one HIV viral load measurement, US$<sup>d</sup></td><td valign="top" align="center" rowspan="1" colspan="1">55.26</td><td valign="top" align="center" rowspan="1" colspan="1">20.34</td><td valign="top" align="center" rowspan="1" colspan="1">119.14</td><td valign="top" align="center" rowspan="1" colspan="1">186.28<sup>f</sup>
</td><td valign="top" align="center" rowspan="1" colspan="1">33.39<sup>g</sup><break/>160.19<sup>h</sup></td><td valign="top" align="center" rowspan="1" colspan="1">119.27</td><td valign="top" align="center" rowspan="1" colspan="1">86.32</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Source of funding for HIV viral load monitoring</td><td valign="top" align="center" rowspan="1" colspan="1">Refund from Argentine government, social insurance</td><td valign="top" align="center" rowspan="1" colspan="1">Brazilian government</td><td valign="top" align="center" rowspan="1" colspan="1">Chilean government</td><td valign="top" align="center" rowspan="1" colspan="1">Research-funded</td><td valign="top" align="center" rowspan="1" colspan="1">Honduran government, social insurance</td><td valign="top" align="center" rowspan="1" colspan="1">Mexican government</td><td valign="top" align="center" rowspan="1" colspan="1">Peruvian government</td></tr></tbody></table><table-wrap-foot><p>ART: antiretroviral therapy; CD4+ cell: CD4+ T lymphocyte; GFATM: Global Fund to Fight AIDS, Tuberculosis and Malaria; HIV: human immunodeficiency virus; MOH: ministry of health; NGO: nongovernmental organization; PAHO: Pan American Health Organization; PEPFAR: The United States President&#x02019;s Emergency Plan for AIDS Relief; SADI: Sociedad Argentina de Infectolog&#x000ed;a; US$: United States dollar; WHO: World Health Organization.</p><p><sup>a</sup> Sites participating in the study are listed in <xref ref-type="boxed-text" rid="B1">Box&#x000a0;1</xref>.</p><p><sup>b</sup> 1991 for monotherapy, 1994 for dual therapy and 1996 for active antiretroviral therapy.</p><p><sup>c</sup> Every six&#x000a0;months for participants with an undetectable viral load, according to the most recent Chilean guidelines (December 2013).</p><p><sup>d</sup> Costs were converted into United States dollars using exchange rates for 9 July 2014. Exchange rates were obtained from the <italic>Wall Street Journal</italic> for Argentina, Brazil, Chile, Mexico and Peru<xref rid="R15" ref-type="bibr">15</xref> and from local central banks for Haiti<xref rid="R16" ref-type="bibr">16</xref> and Honduras.<xref rid="R17" ref-type="bibr">17</xref></p><p><sup>e</sup> Cost quoted by the Peruvian National Institute of Health to public institutions.</p><p><sup>f</sup> Cost for research studies.</p><p><sup>g</sup> Honduran government cost.</p><p><sup>h</sup> Honduran social insurance cost. </p></table-wrap-foot></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Characteristics of participants receiving ART in seven countries in the WHO Region of the Americas, 2000&#x02013;2011</title></caption><table frame="hsides" rules="groups"><col width="241" span="1"/><col width="70" span="1"/><col width="77" span="1"/><col width="70" span="1"/><col width="85" span="1"/><col width="70" span="1"/><col width="70" span="1"/><col width="77" span="1"/><col width="87" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Participants&#x02019; characteristic</th><th colspan="8" valign="top" align="center" scope="colgroup" rowspan="1">Site of adult HIV clinic<sup>a</sup><hr/></th></tr><tr><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">Argentina (<italic>n</italic>&#x02009;=&#x02009;1285)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Brazil (<italic>n</italic>&#x02009;=&#x02009;2446)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Chile (<italic>n</italic>&#x02009;=&#x02009;1080)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Haiti (<italic>n</italic>&#x02009;=&#x02009;5696)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Honduras (<italic>n</italic>&#x02009;=&#x02009;789)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Mexico (<italic>n</italic>&#x02009;=&#x02009;772)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Peru (<italic>n</italic>&#x02009;=&#x02009;2408)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Total (<italic>n</italic>&#x02009;=&#x02009;14&#x02009;476)</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><bold>Age in years, median (IQR)</bold></td><td valign="top" align="center" rowspan="1" colspan="1">39<break/>(33&#x02013;46)</td><td valign="top" align="center" rowspan="1" colspan="1">38<break/>(31&#x02013;46)</td><td valign="top" align="center" rowspan="1" colspan="1">38<break/>(32&#x02013;45)</td><td valign="top" align="center" rowspan="1" colspan="1">39<break/>(32&#x02013;46)</td><td valign="top" align="center" rowspan="1" colspan="1">36<break/>(30&#x02013;43)</td><td valign="top" align="center" rowspan="1" colspan="1">34<break/>(29&#x02013;42)</td><td valign="top" align="center" rowspan="1" colspan="1">35<break/>(29&#x02013;43)</td><td valign="top" align="center" rowspan="1" colspan="1">37<break/>(31&#x02013;45)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><bold>Male sex, no.&#x000a0;(%)</bold></td><td valign="top" align="center" rowspan="1" colspan="1">925 (72)</td><td valign="top" align="center" rowspan="1" colspan="1">1611 (66)</td><td valign="top" align="center" rowspan="1" colspan="1">952 (88)</td><td valign="top" align="center" rowspan="1" colspan="1">2480 (44)</td><td valign="top" align="center" rowspan="1" colspan="1">422 (53)</td><td valign="top" align="center" rowspan="1" colspan="1">673 (87)</td><td valign="top" align="center" rowspan="1" colspan="1">1691 (70)</td><td valign="top" align="center" rowspan="1" colspan="1">8754 (60)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Probable cause of infection, no. (%)</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Heterosexual sex</td><td valign="top" align="center" rowspan="1" colspan="1">340 (26)</td><td valign="top" align="center" rowspan="1" colspan="1">1136 (46)</td><td valign="top" align="center" rowspan="1" colspan="1">285 (26)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">471 (60)</td><td valign="top" align="center" rowspan="1" colspan="1">219 (28)</td><td valign="top" align="center" rowspan="1" colspan="1">1562 (65)</td><td valign="top" align="center" rowspan="1" colspan="1">4013 (28)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Homosexual sex</td><td valign="top" align="center" rowspan="1" colspan="1">181 (14)</td><td valign="top" align="center" rowspan="1" colspan="1">833 (34)</td><td valign="top" align="center" rowspan="1" colspan="1">785 (73)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">49 (6)</td><td valign="top" align="center" rowspan="1" colspan="1">514 (67)</td><td valign="top" align="center" rowspan="1" colspan="1">831 (35)</td><td valign="top" align="center" rowspan="1" colspan="1">3193 (22)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Other</td><td valign="top" align="center" rowspan="1" colspan="1">55 (4)</td><td valign="top" align="center" rowspan="1" colspan="1">81 (3)</td><td valign="top" align="center" rowspan="1" colspan="1">9 (1)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">17 (2)</td><td valign="top" align="center" rowspan="1" colspan="1">13 (1)</td><td valign="top" align="center" rowspan="1" colspan="1">178 (1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Unknown</td><td valign="top" align="center" rowspan="1" colspan="1">709 (55)</td><td valign="top" align="center" rowspan="1" colspan="1">396 (16)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">5696 (100)</td><td valign="top" align="center" rowspan="1" colspan="1">266 (34)</td><td valign="top" align="center" rowspan="1" colspan="1">22 (3)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">7092 (49)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>CD4+ cell count at ART initiation, no.&#x000a0;(%)</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Data missing</td><td valign="top" align="center" rowspan="1" colspan="1">306 (24)</td><td valign="top" align="center" rowspan="1" colspan="1">426 (17)</td><td valign="top" align="center" rowspan="1" colspan="1">302 (28)</td><td valign="top" align="center" rowspan="1" colspan="1">772 (14)</td><td valign="top" align="center" rowspan="1" colspan="1">151 (19)</td><td valign="top" align="center" rowspan="1" colspan="1">132 (17)</td><td valign="top" align="center" rowspan="1" colspan="1">326 (14)</td><td valign="top" align="center" rowspan="1" colspan="1">2415 (17)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">200&#x02013;350&#x000a0;cells/&#x000b5;L &#x0003c;&#x02009;200&#x000a0;cells/&#x000b5;L</td><td valign="top" align="center" rowspan="1" colspan="1">306 (24)</td><td valign="top" align="center" rowspan="1" colspan="1">771 (32)</td><td valign="top" align="center" rowspan="1" colspan="1">373 (35)</td><td valign="top" align="center" rowspan="1" colspan="1">3035 (53)</td><td valign="top" align="center" rowspan="1" colspan="1">447 (57)</td><td valign="top" align="center" rowspan="1" colspan="1">355 (45)</td><td valign="top" align="center" rowspan="1" colspan="1">1222 (51)</td><td valign="top" align="center" rowspan="1" colspan="1">6509 (45)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">200&#x02013;350&#x000a0;cells/&#x000b5;L</td><td valign="top" align="center" rowspan="1" colspan="1">349 (27)</td><td valign="top" align="center" rowspan="1" colspan="1">650 (27)</td><td valign="top" align="center" rowspan="1" colspan="1">234 (22)</td><td valign="top" align="center" rowspan="1" colspan="1">1537 (27)</td><td valign="top" align="center" rowspan="1" colspan="1">146 (19)</td><td valign="top" align="center" rowspan="1" colspan="1">184 (24)</td><td valign="top" align="center" rowspan="1" colspan="1">526 (22)</td><td valign="top" align="center" rowspan="1" colspan="1">3626 (25)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">350&#x000a0;cells/&#x000b5;L</td><td valign="top" align="center" rowspan="1" colspan="1">324 (25)</td><td valign="top" align="center" rowspan="1" colspan="1">599 (24)</td><td valign="top" align="center" rowspan="1" colspan="1">171 (16)</td><td valign="top" align="center" rowspan="1" colspan="1">352 (6)</td><td valign="top" align="center" rowspan="1" colspan="1">45 (6)</td><td valign="top" align="center" rowspan="1" colspan="1">101 (13)</td><td valign="top" align="center" rowspan="1" colspan="1">334 (14)</td><td valign="top" align="center" rowspan="1" colspan="1">1926 (13)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><bold>Prior AIDS-defining event<sup>b</sup> at ART initiation, no. (%)</bold></td><td valign="top" align="center" rowspan="1" colspan="1">54 (4)</td><td valign="top" align="center" rowspan="1" colspan="1">172 (7)</td><td valign="top" align="center" rowspan="1" colspan="1">292 (27)</td><td valign="top" align="center" rowspan="1" colspan="1">1223 (21)</td><td valign="top" align="center" rowspan="1" colspan="1">252 (32)</td><td valign="top" align="center" rowspan="1" colspan="1">332 (43)</td><td valign="top" align="center" rowspan="1" colspan="1">848 (35)</td><td valign="top" align="center" rowspan="1" colspan="1">3173 (22)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><bold>Prior AIDS-defining event or CD4+ cell count &#x0003c;&#x02009;200&#x000a0;cells/&#x000b5;L at ART initiation</bold></td><td valign="top" align="center" rowspan="1" colspan="1">335 (26)</td><td valign="top" align="center" rowspan="1" colspan="1">871 (36)</td><td valign="top" align="center" rowspan="1" colspan="1">541 (50)</td><td valign="top" align="center" rowspan="1" colspan="1">3423 (60)</td><td valign="top" align="center" rowspan="1" colspan="1">536 (68)</td><td valign="top" align="center" rowspan="1" colspan="1">486 (63)</td><td valign="top" align="center" rowspan="1" colspan="1">1515 (63)</td><td valign="top" align="center" rowspan="1" colspan="1">7707 (53)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><bold>NNRTI-based ART regimen, no. (%)</bold></td><td valign="top" align="center" rowspan="1" colspan="1">869 (68)</td><td valign="top" align="center" rowspan="1" colspan="1">1270 (52)</td><td valign="top" align="center" rowspan="1" colspan="1">858 (79)</td><td valign="top" align="center" rowspan="1" colspan="1">5279 (93)</td><td valign="top" align="center" rowspan="1" colspan="1">745 (94)</td><td valign="top" align="center" rowspan="1" colspan="1">607 (79)</td><td valign="top" align="center" rowspan="1" colspan="1">2024 (84)</td><td valign="top" align="center" rowspan="1" colspan="1">11 652 (80)</td></tr></tbody></table><table-wrap-foot><p>AIDS: acquired immune deficiency syndrome; ART: antiretroviral therapy; CD4+ cell: CD4+ T lymphocyte; HIV: human immunodeficiency virus; IQR: interquartile range; NNRTI: non-nucleoside reverse transcriptase inhibitor; WHO: World Health Organization.</p><p><sup>a</sup> Sites participating in the study are listed in <xref ref-type="boxed-text" rid="B1">Box&#x000a0;1</xref>.</p><p><sup>b</sup> A participant had an AIDS-defining event if they had clinical disease that could be classified as Centers for Disease Control and Prevention category C or WHO stage&#x000a0;IV.</p></table-wrap-foot></table-wrap><sec><title>Frequency and cost</title><p>The frequency and cost of CD4+ cell counts and viral load measurements varied according to the study site (<xref ref-type="table" rid="T3">Table&#x000a0;3</xref>). The median frequency of CD4+ cell counts ranged from 2.6 per year in Argentina and Mexico to 1.0 per year in Haiti and the median frequency of viral load measurements ranged from 2.6 per year in Argentina and Mexico to 0.9 per year in Honduras. The annual cost per participant of CD4+ cell count and viral load monitoring was US$&#x000a0;38 and US$&#x000a0;140, respectively (<xref ref-type="table" rid="T3">Table&#x000a0;3</xref>). However the cost varied greatly between sites: the median cost of monitoring the CD4+ cell count ranged from US$&#x000a0;18 per participant per year in Honduras to US$&#x000a0;154 in Mexico and the median cost of monitoring the viral load ranged from US$&#x000a0;41 per participant per year in Brazil to US$&#x000a0;310 in Mexico. There was no significant correlation between the frequency and cost of CD4+ cell counts (rank correlation: &#x02212;0.18, <italic>P</italic>&#x02009;=&#x02009;0.71) or the frequency and cost of viral load measurements (rank correlation: &#x02212;0.29, <italic>P</italic>&#x02009;=&#x02009;0.56).</p><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Antiretroviral treatment monitoring in seven countries in the WHO Region of the Americas, 2000&#x02013;2011</title></caption><table frame="hsides" rules="groups"><col width="148" span="1"/><col width="92" span="1"/><col width="85" span="1"/><col width="92" span="1"/><col width="85" span="1"/><col width="85" span="1"/><col width="92" span="1"/><col width="92" span="1"/><col width="85" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Monitoring test</th><th colspan="8" valign="top" align="center" scope="colgroup" rowspan="1">Site of adult HIV clinic<sup>a</sup><hr/></th></tr><tr><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">Argentina (<italic>n</italic>&#x02009;=&#x02009;1285)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Brazil (<italic>n</italic>&#x02009;=&#x02009;2446)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Chile (<italic>n</italic>&#x02009;=&#x02009;1080)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Haiti (<italic>n</italic>&#x02009;=&#x02009;5696)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Honduras (<italic>n</italic>&#x02009;=&#x02009;789)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Mexico (<italic>n</italic>&#x02009;=&#x02009;772)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Peru (<italic>n</italic>&#x02009;=&#x02009;2408)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Total (<italic>n</italic>&#x02009;=&#x02009;14&#x02009;476)</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>CD4+ cell count</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">No. of measurements per year, median (IQR)</td><td valign="top" align="center" rowspan="1" colspan="1">2.6 <break/>(1.9&#x02013;3.2)</td><td valign="top" align="center" rowspan="1" colspan="1">2.1 <break/>(1.5&#x02013;2.6)</td><td valign="top" align="center" rowspan="1" colspan="1">1.7 <break/>(1.4&#x02013;2.0)</td><td valign="top" align="center" rowspan="1" colspan="1">1.0 <break/>(0.7&#x02013;1.3)</td><td valign="top" align="center" rowspan="1" colspan="1">1.3 <break/>(0.9&#x02013;1.6)</td><td valign="top" align="center" rowspan="1" colspan="1">2.6 <break/>(2.2&#x02013;3.1)</td><td valign="top" align="center" rowspan="1" colspan="1">1.8<break/>(1.4&#x02013;2.1)</td><td valign="top" align="center" rowspan="1" colspan="1">1.5<break/>(0.9&#x02013;2.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Cost per year in US$,<sup>b</sup> median (IQR)</td><td valign="top" align="center" rowspan="1" colspan="1">19<break/>(14&#x02013;24)</td><td valign="top" align="center" rowspan="1" colspan="1">36<break/>(26&#x02013;45)</td><td valign="top" align="center" rowspan="1" colspan="1">112<break/>(87&#x02013;130)</td><td valign="top" align="center" rowspan="1" colspan="1">33<break/>(24&#x02013;44)</td><td valign="top" align="center" rowspan="1" colspan="1">18<break/>(13&#x02013;22)</td><td valign="top" align="center" rowspan="1" colspan="1">154<break/>(132&#x02013;183)</td><td valign="top" align="center" rowspan="1" colspan="1">68<break/>(55&#x02013;78)</td><td valign="top" align="center" rowspan="1" colspan="1">38<break/>(24&#x02013;63)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>HIV viral load<sup>c</sup></bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">No. of measurements per year, median (IQR)</td><td valign="top" align="center" rowspan="1" colspan="1">2.6<break/>(1.9&#x02013;3.3)</td><td valign="top" align="center" rowspan="1" colspan="1">2.0<break/>(1.4&#x02013;2.5)</td><td valign="top" align="center" rowspan="1" colspan="1">1.8<break/>(1.4&#x02013;2.0)</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">0.9<break/>(0.6&#x02013;1.3)</td><td valign="top" align="center" rowspan="1" colspan="1">2.6<break/>(2.2&#x02013;3.1)</td><td valign="top" align="center" rowspan="1" colspan="1">1.9<break/>(1.5&#x02013;2.1)</td><td valign="top" align="center" rowspan="1" colspan="1">1.9<break/>(1.4&#x02013;2.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Cost per year in US$,<sup>b</sup> median (IQR)</td><td valign="top" align="center" rowspan="1" colspan="1">145<break/>(106&#x02212;180)</td><td valign="top" align="center" rowspan="1" colspan="1">41<break/>(29&#x02013;51)</td><td valign="top" align="center" rowspan="1" colspan="1">210<break/>(169&#x02013;240)</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">138<break/>(91&#x02013;207)</td><td valign="top" align="center" rowspan="1" colspan="1">310<break/>(265&#x02013;369)</td><td valign="top" align="center" rowspan="1" colspan="1">162<break/>(133&#x02013;184)</td><td valign="top" align="center" rowspan="1" colspan="1">140<break/>(52&#x02013;194)</td></tr></tbody></table><table-wrap-foot><p>CD4+ cell: CD4+ T lymphocyte; HIV: human immunodeficiency virus; IQR: interquartile range; NA: not applicable; US$: United States dollar; WHO: World Health Organization.</p><p><sup>a</sup> Sites participating in the study are listed in <xref ref-type="boxed-text" rid="B1">Box&#x000a0;1</xref>.</p><p><sup>b</sup> Costs were converted into United States dollars using exchange rates for 9 July 2014. Exchange rates were obtained from the <italic>Wall Street Journal</italic> for Argentina, Brazil, Chile, Mexico and Peru<xref rid="R15" ref-type="bibr">15</xref> and from local central banks for Haiti<xref rid="R16" ref-type="bibr">16</xref> and Honduras.<xref rid="R17" ref-type="bibr">17</xref></p><p><sup>c</sup> Viral load was assessed by measuring the plasma HIV-RNA level.</p></table-wrap-foot></table-wrap></sec><sec><title>Adherence to guidelines</title><p>The adequacy of CD4+ cell count and viral load monitoring is shown for each site in <xref ref-type="fig" rid="F1">Fig.&#x000a0;1</xref>. The proportion of periods with adequate monitoring was highest in Mexico (86%) and Argentina (80%) but much lower in Honduras (26%). Across the six sites for which data were available, the proportion of periods with adequate CD4+ cell count and viral load monitoring was 62% (95% confidence interval, CI: 52&#x02013;73) &#x02013; the large confidence interval was due to the substantial variation between sites. <xref ref-type="fig" rid="F2">Fig.&#x000a0;2</xref> shows the proportion of 180-day periods with adequate CD4+ cell count monitoring alone. Overall, the proportions were higher than those observed for CD4+ cell count and viral load monitoring combined and ranged from 86% and 81% in Mexico and Argentina, respectively, to 54% and 48% in Honduras and Haiti, respectively. Across all seven sites, the proportion of periods with adequate CD4+ cell count monitoring alone was 69% (95% CI:&#x02009;57&#x02013;82). General trends were similar in sensitivity analyses that included periods of less than 180&#x000a0;days (data available from corresponding author).</p><fig id="F1" fig-type="figure" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Adequate CD4+ cell count and HIV viral load monitoring in six countries in the WHO Region of the Americas, 2000&#x02013;2011</p></caption><p>CD4+ cell: CD4+ T lymphocyte; HIV: human immunodeficiency virus; WHO: World Health Organization.</p><p>Notes: Monitoring was defined as adequate if at least one CD4+ cell count and one viral load measurement were made in each 180-day follow-up period. Sites participating in the study are listed in <xref ref-type="boxed-text" rid="B1">Box&#x000a0;1</xref>. The site in Haiti did not assess viral load during the study period.</p><graphic xlink:href="BLT.14.147447-F1"/></fig><fig id="F2" fig-type="figure" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Adequate CD4+ cell count monitoring in seven countries in the WHO Region of the Americas, 2000&#x02013;2011</p></caption><p>CD4+ cell: CD4+ T lymphocyte; HIV: human immunodeficiency virus; WHO: World Health Organization.</p><p>Notes: Monitoring was defined as adequate if at least one CD4+ cell count measurement was made in each 180-day follow-up period. Sites participating in the study are listed in <xref ref-type="boxed-text" rid="B1">Box&#x000a0;1</xref>.</p><graphic xlink:href="BLT.14.147447-F2"/></fig><p>Factors associated with adequate CD4+ cell count and viral load monitoring at each site and across all sites combined were identified. At all sites, adequate CD4+ cell count and viral load monitoring was more likely in older participants (<xref ref-type="fig" rid="F3">Fig.&#x000a0;3</xref>) and in those who started ART more recently (<xref ref-type="fig" rid="F4">Fig.&#x000a0;4</xref>). Patients with a CD4+ cell count less than 200&#x000a0;cells/&#x000b5;L at ART initiation were more likely to have adequate monitoring than those with a count more than 350&#x000a0;cells/&#x000b5;L (<xref ref-type="fig" rid="F5">Fig.&#x000a0;5</xref>). Participants whose first ART regimen contained a non-nucleoside reverse transcriptase inhibitor were also more likely to have adequate monitoring than those treated with other regimens (<xref ref-type="fig" rid="F6">Fig.&#x000a0;6</xref>). Neither sex, a CD4+ cell count in the range 200 to 350&#x000a0;cells/&#x000b5;L nor prior AIDS-defining events influenced the likelihood of adequate CD4+ cell count and viral load monitoring.</p><fig id="F3" fig-type="figure" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>Adequate CD4+ cell count and HIV viral load monitoring in six countries in the WHO Region of the Americas, 2000&#x02013;2011: rate ratio for a 10-year increase in age</p></caption><p>CD4+ cell: CD4+ T lymphocyte; CI: confidence interval; HIV: human immunodeficiency virus; RR: rate ratio; WHO: World Health Organization.</p><p>Notes: Monitoring was defined as adequate if at least one CD4+ cell count and one viral load measurement were made in each 180-day follow-up period.</p><p>Points to the right of the vertical line indicate that older participants are more likely to be adequately monitored. Sites participating in the study are listed in <xref ref-type="boxed-text" rid="B1">Box&#x000a0;1</xref>. The site in Haiti did not assess viral load during the study period. </p><graphic xlink:href="BLT.14.147447-F3"/></fig><fig id="F4" fig-type="figure" orientation="portrait" position="float"><label>Fig. 4</label><caption><p>Adequate CD4+ cell count and HIV viral load monitoring in six countries in the WHO Region of the Americas, 2000&#x02013;2011: rate ratio for a 1-year reduction in time since ART initiation</p></caption><p>ART: antiretroviral therapy; CD4+ cell: CD4+ T lymphocyte; CI: confidence interval; HIV: human immunodeficiency virus; RR: rate ratio; WHO: World Health Organization.</p><p>Notes: Monitoring was defined as adequate if at least one CD4+ cell count and one viral load measurement were made in each 180-day follow-up period. Points to the right of the vertical line indicate that participants who started ART more recently are more likely to be adequately monitored. RR per calendar year increase in the date of ART initiation. Sites participating in the study are listed in <xref ref-type="boxed-text" rid="B1">Box&#x000a0;1</xref>. The site in Haiti did not assess viral load during the study period.</p><graphic xlink:href="BLT.14.147447-F4"/></fig><fig id="F5" fig-type="figure" orientation="portrait" position="float"><label>Fig. 5</label><caption><p>Adequate CD4+ cell count and HIV viral load monitoring in six countries in the WHO Region of the Americas, 2000&#x02013;2011:rate ratio for CD4+ T-cell count at ART initiation &#x0003e;350 cells/ &#x000b5;L versus &#x0003c;200 cells/&#x000b5;L</p></caption><p>ART: antiretroviral therapy; CD4+ cell: CD4+ T lymphocyte; CI: confidence interval; HIV: human immunodeficiency virus; RR: rate ratio; WHO: World Health Organization.</p><p>Notes: Monitoring was defined as adequate if at least one CD4+ cell count and one viral load measurement were made in each 180-day follow-up period. Points to the left of the vertical line indicate that participants with higher cell count at ART initiation are less likely to be adequately monitored. Sites participating in the study are listed in <xref ref-type="boxed-text" rid="B1">Box&#x000a0;1</xref>. The site in Haiti did not assess viral load during the study period.</p><graphic xlink:href="BLT.14.147447-F5"/></fig><fig id="F6" fig-type="figure" orientation="portrait" position="float"><label>Fig. 6</label><caption><p>Adequate CD4+ cell count and HIV viral load monitoring in six countries in the WHO Region of the Americas, 2000&#x02013;2011: rate ratio for nucleoside reverse transcriptase inhibitor regimen versus NNRTI regimen</p></caption><p>ART: antiretroviral therapy; CD4+ cell: CD4+ T lymphocyte; CI: confidence interval; HIV: human immunodeficiency virus; NNRTI: non-nucleoside reverse transcriptase inhibitor; RR: rate ratio; WHO: World Health Organization.</p><p>Notes: Monitoring was defined as adequate if at least one CD4+ cell count and one viral load measurement were made in each 180-day follow-up period. Points to the left of the vertical line indicate that participants who were on a NNRTI regimen were less likely to be inadequately monitored. Sites participating in the study are listed in <xref ref-type="boxed-text" rid="B1">Box&#x000a0;1</xref>. The site in Haiti did not assess viral load during the study period.</p><graphic xlink:href="BLT.14.147447-F6"/></fig><p>Factors associated with adequate CD4+ cell count monitoring alone were also identified. Again, adequate monitoring was more likely in older participants (<xref ref-type="fig" rid="F7">Fig.&#x000a0;7</xref>) and in those whose first ART regimen contained a non-nucleoside reverse transcriptase inhibitor (<xref ref-type="fig" rid="F8">Fig.&#x000a0;8</xref>). Sensitivity analyses that included periods shorter than 180&#x000a0;days yielded similar results (details available from the corresponding author). Neither sex, prior AIDS-defining events, nor the year of ART initiation influenced the likelihood of adequate CD4+ cell count monitoring, though there was some indication that a CD4+ cell count less than 200&#x000a0;cells/&#x000b5;L at ART initiation may have had an effect.</p><fig id="F7" fig-type="figure" orientation="portrait" position="float"><label>Fig. 7</label><caption><p>Adequate CD4+ cell count monitoring in seven countries in the WHO Region of the Americas, 2000&#x02013;2011: rate ratio for a 10-year increase in age</p></caption><p>CD4+ cell: CD4+ T lymphocyte; CI: confidence interval; HIV: human immunodeficiency virus; RR: rate ratio; WHO: World Health Organization.</p><p>Notes: Monitoring was defined as adequate if at least one CD4+ cell count measurement was made in each 180-day follow-up period. Points to the right of the vertical line indicate that older participants are more likely to be adequately monitored. Sites participating in the study are listed in <xref ref-type="boxed-text" rid="B1">Box&#x000a0;1</xref>.</p><graphic xlink:href="BLT.14.147447-F7"/></fig><fig id="F8" fig-type="figure" orientation="portrait" position="float"><label>Fig. 8</label><caption><p>Adequate CD4+ cell count monitoring in seven countries in the WHO Region of the Americas, 2000&#x02013;2011</p></caption><p>ART: antiretroviral therapy; CD4+ cell: CD4+ T lymphocyte; CI: confidence interval; HIV: human immunodeficiency virus; NNRTI: non-nucleoside reverse transcriptase inhibitor; RR: rate ratio; WHO: World Health Organization.</p><p>Notes: Monitoring was defined as adequate if at least one CD4+ cell count measurement was made in each 180-day follow-up period. Points to the left of the vertical line indicate that participants who were on a NNRTI regimen were less likely to be inadequately monitored. Sites participating in the study are listed in <xref ref-type="boxed-text" rid="B1">Box&#x000a0;1</xref>.</p><graphic xlink:href="BLT.14.147447-F8"/></fig></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>We found that HIV-infected people starting ART at seven sites in the region were monitored less frequently than recommended by regional and national clinical guidelines. On average, CD4+ cell count and viral load monitoring were done at least once every six&#x000a0;months for only 62% of the time participants were in care, although the proportion varied greatly across sites. The equivalent proportion for CD4+ cell count monitoring alone was 69%. Adequate monitoring of both parameters was associated with older age at ART initiation, receiving ART in more recent years, starting ART when the CD4+ cell count was less than 200&#x000a0;cells/&#x000b5;L and a first ART regimen that included a non-nucleoside reverse transcriptase inhibitor.</p><p>The annual cost of CD4+ cell count and viral load monitoring per participant varied greatly between countries. For instance, the annual cost of CD4+ cell count monitoring per participant in Mexico was around four times the median cost in the region and almost nine times the cost in Honduras. Although we are not aware of previous studies of the cost of monitoring ART efficacy in the region, the Pan American Health Organization (PAHO) recently noted that the annual cost of ART medications per participant in the most expensive countries was approximately 10 times that in the lowest-cost countries.<xref rid="R18" ref-type="bibr">18</xref> These differences have been attributed to the varying use of generic drugs and to the ART procurement mechanism preferred by each country.<xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R19" ref-type="bibr">19</xref></p><p>The implications of the variability in monitoring costs across the region we observed are difficult to discern. For instance, although it appears that the cost of CD4+ cell count and viral load monitoring at individual sites was not related to the frequency of monitoring or to adherence to guideline recommendations, we were not able to assess how cost differences affected participant care, such as the ability to detect treatment failure. Furthermore, it would be difficult to use our results to identify a single initiative that could reduce costs across the region because each centre itself negotiates costs and budgets with local laboratories and with different sponsors. For the large centres in Argentina, Brazil, Chile and Peru, it may be possible to reduce costs by exploiting the large demand to leverage services. However, this strategy may not work for centres in Haiti, Honduras or Mexico, where government and international funding agencies, or the local infrastructure, may restrict their ability to negotiate costs locally.</p><p>The frequency of CD4+ cell count and viral load monitoring we observed in HIV-infected persons receiving ART was very similar to that reported in the region by PAHO.<xref rid="R20" ref-type="bibr">20</xref> It is possible to divide our sites into two groups: those where participants were followed up in accordance with clinical guidelines most of the time (i.e. Argentina, Brazil, Chile, Mexico and Peru) and those where participants were followed up in accordance with guidelines less than half the time (i.e. Haiti and Honduras). It is noteworthy that the proportion of periods when CD4+ cell count and viral load monitoring was adequate was very similar to the proportion when CD4+ cell count monitoring alone was adequate at all sites except Haiti, which did not measure viral load, and Honduras, where in practice laboratory monitoring of the efficacy of ART was based more on CD4+ cell counts alone, than on both CD4+ cell count and viral load monitoring.</p><p>The low level of adherence to clinical guidelines we observed was probably due to a combination of factors related to the participants, physicians and other health-care providers and, more generally, to structural and programmatic characteristics. At the individual level, our findings agree with those of previous studies in identifying older age as an important factor associated with adherence to ART,<xref rid="R21" ref-type="bibr">21</xref> adequate CD4+ cell count monitoring, retention on treatment and fewer missed clinic visits.<xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R23" ref-type="bibr">23</xref> We found that a CD4+ cell count less than 200&#x000a0;cells/&#x000b5;L at ART initiation was associated with adequate CD4+ cell count monitoring overall, but not at most individual sites. We hypothesize that clinicians&#x02019; perception that profound immunosuppression is associated with an increased risk of complications may have led to more frequent monitoring.</p><p>Although we were not able to evaluate structural and programmatic characteristics in detail, we observed several factors that could explain some of the differences in monitoring between sites. For example, the Global Fund to Fight AIDS, Tuberculosis and Malaria did not cover the cost of viral load measurements in Haiti and, consequently, this test was little used. Haiti and Honduras have generalized HIV epidemics, whereas in the rest of the region HIV infection is concentrated among men who have sex with men and injection-drug users.<xref rid="R24" ref-type="bibr">24</xref> There were also clear differences in national income, development indices and health expenditure per capita<xref rid="R25" ref-type="bibr">25</xref> between Haiti and Honduras and the other countries we studied.<xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R26" ref-type="bibr">26</xref> Although the maturity of universal ART access programmes could have influenced adherence to clinical guidelines, most countries in the region, including Haiti and Honduras, expanded their programmes between 2002 and 2003 and quickly ensured that most people in need of ART received treatment. Finally, the site in Haiti has been actively involved in emergency responses to the earthquake in 2010 and to the ensuing cholera epidemic in 2012,<xref rid="R27" ref-type="bibr">27</xref> which may have diverted resources from HIV-related health care. It is possible that viral load monitoring in Haiti could be increased if the Global Fund updated its policy on funding monitoring or PAHO changed its recommendations on monitoring. However, detailed research on differences in treatment programmes across a larger number of centres is needed to clearly identify policies that could improve adherence to clinical guidelines and reduce costs.</p><p>Our study has several limitations. First, we used a conservative definition of adequate CD4+ cell count and viral load monitoring &#x02013; six&#x000a0;months is currently the maximum time interval recommended by the guidelines used at all sites and most countries in the region recommend measurements every three to four&#x000a0;months.<xref rid="R5" ref-type="bibr">5</xref>&#x02013;<xref rid="R10" ref-type="bibr">10</xref> Thus, we may have overestimated adherence to recommendations. Since we were not able to identify reasons for poor adherence or for the wide range in monitoring costs, it is difficult to propose interventions that would improve adherence or decrease costs. Another limitation is that it is not clear whether poor adherence to laboratory monitoring guidelines was associated with worse outcomes in HIV-infected people in the region. Certainly, virological failure will be detected less often if fewer viral load measurements are done and this may lead to poorer clinical outcomes. Earlier research at our study sites found that mortality was generally higher in Haiti and Honduras,<xref rid="R28" ref-type="bibr">28</xref> where monitoring was less frequent, but the high mortality was probably due to several factors and not to monitoring practices alone. Previous studies in Africa and mathematical modelling suggest that carrying out laboratory monitoring less frequently than recommended may have negative consequences for the health of people on ART and that measuring the viral load two or three times a year may be more cost-effective and reduce HIV transmission.<xref rid="R29" ref-type="bibr">29</xref>,<xref rid="R30" ref-type="bibr">30</xref> However, the clinical and cost benefits of measuring both the CD4+ cell count and viral load as frequently as currently recommended are still debated.<xref rid="R31" ref-type="bibr">31</xref>&#x02013;<xref rid="R35" ref-type="bibr">35</xref> A randomized trial may be required to resolve the issue.</p><p>In conclusion, adherence to recommended CD4+ cell count and viral load monitoring frequencies was generally poor in the region, with large variations between sites. Laboratory costs were also highly variable. Further research is needed to identify the underlying cause of differences in the frequency and cost of monitoring across the region and studies should be carried out to evaluate the impact of less frequent laboratory monitoring on health outcomes in HIV-infected persons receiving ART. We hope our study findings will be helpful for developing and implementing HIV treatment guidelines.</p></sec></body><back><ack><title>Acknowledgements</title><p>We thank all participants, caregivers and data managers at the CCASAnet sites.</p></ack><fn-group><title>Funding:</title><fn fn-type="supported-by"><p>This work was supported by the United States National Institute of Allergy and Infectious Diseases (NIAID) as part of the International Epidemiologic Databases to Evaluate AIDS (IeDEA) network: U01 AI069923. Pablo Belaunzar&#x000e1;n-Zamudio received funding for postgraduate studies from the Mexican National Council for Science and Technology (CONACYT).</p></fn></fn-group><fn-group><title>Competing interests:</title><fn fn-type="financial-disclosure"><p>None declared.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal"><string-name><surname>Lanoy</surname>
<given-names>E</given-names></string-name>, <string-name><surname>May</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Mocroft</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Phillip</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Justice</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Ch&#x000ea;ne</surname>
<given-names>G</given-names></string-name>, <etal>et al.</etal>, <collab>Antiretroviral therapy cohort collaboration (ART-CC)</collab>. <article-title>Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4+ cell count and plasma HIV-1 RNA measurements.</article-title>
<source>AIDS</source>. <year>2009</year>
<month>10</month>
<day>23</day>;<volume>23</volume>(<issue>16</issue>):<fpage>2199</fpage>&#x02013;<lpage>208</lpage>. <pub-id pub-id-type="doi">10.1097/QAD.0b013e3283305a00</pub-id><pub-id pub-id-type="pmid">19779320</pub-id></mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="web">Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2013. Available from: <ext-link ext-link-type="uri" xlink:href="http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf?ua=1">http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf?ua=1</ext-link> [cited 2014 Jul 22].</mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="web">Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [Internet]. Rockville: AIDSinfo; 2015. Available from: <ext-link ext-link-type="uri" xlink:href="http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf">http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf</ext-link> [cited 2014 Sep 18].</mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="web">Pautas de tratamiento antirretroviral en adultos para pa&#x000ed;ses de Latinoam&#x000e9;rica y el Caribe: recomendaciones de un grupo consultor. Washington: Organizaci&#x000f3;n Panamericana de la Salud; 2002. Available from: <ext-link ext-link-type="uri" xlink:href="http://www1.paho.org/spanish/ad/fch/ai/arv_adultos.htm">http://www1.paho.org/spanish/ad/fch/ai/arv_adultos.htm</ext-link> [cited 2013 Apr 25]. Spanish.</mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="web">Recomendaciones para el seguimiento y tratamiento de la infecci&#x000f3;n por HIV/SIDA y sus comorbilidades asociadas. Buenos Aires: Sociedad Argentina de Infectologia; 2012. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.sadi.org.ar/index.php/recomendaciones-y-consensos/item/52-recomendaciones-para-el-seguimiento-y-tratamiento-de-la-infeccion-por-hiv-siday-sus-comorbilidades-asociadas">http://www.sadi.org.ar/index.php/recomendaciones-y-consensos/item/52-recomendaciones-para-el-seguimiento-y-tratamiento-de-la-infeccion-por-hiv-siday-sus-comorbilidades-asociadas</ext-link> [cited 2013 Apr 18]. Spanish.</mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="web">Gu&#x000ed;a para el manejo de los pacientes adultos con infecci&#x000f3;n por VIH. Buenos Aires: Direcci&#x000f3;n de Sida y ETS, Ministerio de Salud; 2013. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.msal.gov.ar/images/stories/bes/graficos/0000000109cnt-2013-05_guia-manejo-pacientes-adultos.pdf">http://www.msal.gov.ar/images/stories/bes/graficos/0000000109cnt-2013-05_guia-manejo-pacientes-adultos.pdf</ext-link> [cited 2014 Sep 2]. Spanish</mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="web">Recomenda&#x000e7;&#x000f5;es para terapia anti-retroviral em adultos infectados pelo HIV. Bras&#x000ed;lia: Programa Nacional de DST e Aids, Secretaria de Vigil&#x000e2;ncia em Sa&#x000fa;de, Minist&#x000e9;rio da Sa&#x000fa;de; 2008. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/hiv/pub/guidelines/brazil_art.pdf">http://www.who.int/hiv/pub/guidelines/brazil_art.pdf</ext-link> [cited 2013 Apr 25]. Portuguese.</mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="web">Gu&#x000ed;a cl&#x000ed;nica: s&#x000ed;ndrome de inmunodeficiencia adquirida VIH/SIDA. Santiago: Ministerio de Salud; 2010. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/hiv/pub/guidelines/chile_art.pdf">http://www.who.int/hiv/pub/guidelines/chile_art.pdf</ext-link> [cited 2013 Apr 25]. Spanish.</mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="web">Gu&#x000ed;a de manejo antirretroviral de las personas con VIH. 5th edition. M&#x000e9;xico Distrito Federal: Centro Nacional para la Prevencion y Control del VIH/Sida; 2012. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.censida.salud.gob.mx/descargas/atencion/GUIA_ARV_2012.pdf">http://www.censida.salud.gob.mx/descargas/atencion/GUIA_ARV_2012.pdf</ext-link>. [cited 2013 Apr 25]. Spanish.</mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="web">Norma t&#x000e9;cnica para el tratamiento antirretroviral de gran actividad &#x02013; TARGA en adultos infectados por el virus de la inmunodeficiencia humana. Lima: Ministerio de Salud; 2005. Available from: <ext-link ext-link-type="uri" xlink:href="http://www2.paho.org/hq/dmdocuments/2010/Peru-ADULTOS-2005.pdf">http://www2.paho.org/hq/dmdocuments/2010/Peru-ADULTOS-2005.pdf</ext-link> [cited 2013 May 1]. Spanish.</mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="web">Global report: UNAIDS report on the global AIDS epidemic 2013. Geneva: Joint United Nations Programme on HIV/AIDS; 2013. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Global_Report_2013_en_1.pdf">http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Global_Report_2013_en_1.pdf</ext-link> [cited 2015 Apr 30].</mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal"><string-name><surname>Nelson</surname>
<given-names>LJ</given-names></string-name>, <string-name><surname>Beusenberg</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Habiyambere</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Shaffer</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Vitoria</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Montero</surname>
<given-names>RG</given-names></string-name>, <etal>et al.</etal>
<article-title>Adoption of national recommendations related to use of antiretroviral therapy before and shortly following the launch of the 2013 WHO consolidated guidelines.</article-title>
<source>AIDS</source>. <year>2014</year>
<month>3</month>;<volume>28</volume>
<issue>Suppl 2</issue>:<fpage>S217</fpage>&#x02013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1097/QAD.0000000000000239</pub-id><pub-id pub-id-type="pmid">24849481</pub-id></mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="web">Caribbean, central and south America network for HIV epidemiology (CCASAnet) [Internet]. Nashville: CCASAnet; 2015. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.ccasanet.org">www.ccasanet.org</ext-link> [cited 2015 Apr 30].</mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="web">International epidemiologic databases to evaluate AIDS (IeDEA) [Internet]. Bethesda: National Institute of Allergy and Infectious Diseases; 2015. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.iedea.org">www.iedea.org</ext-link> [cited 2015 Apr 30].</mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="web">Exchange rates: New York closing snapshot [Internet]. New York: The Wall Street Journal; July 9 2014. Available from: <ext-link ext-link-type="uri" xlink:href="http://online.wsj.com/mdc/public/page/2_3021-forex.html">http://online.wsj.com/mdc/public/page/2_3021-forex.html</ext-link> [cited 2014 Jul 10].</mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="web">Taux de reference [Internet]. Port-au-Prince: Banque de la R&#x000e9;publique d'Ha&#x000ef;ti; 16 July 2014. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.brh.net/tauxdujour.htm">http://www.brh.net/tauxdujour.htm</ext-link> [cited 2014 Jul 16]. Spanish.</mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="web">Cotizaci&#x000f3;n del D&#x000f3;lar [Internet]. Tegucigalpa: Banco Central de Honduras; 10 July 2014. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.bch.hn/index.php">http://www.bch.hn/index.php</ext-link> [cited 2014 Jul 10].Spanish.</mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="book">Tratamiento antirretroviral bajo la lupa: un an&#x000e1;lisis de salud p&#x000fa;blica en Latinoam&#x000e9;rica y el Caribe. Washington: Organizaci&#x000f3;n Panamericana de la Salud; 2012. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.bvsde.paho.org/documentosdigitales/bvsde/texcom/cd045364/TAR_BajoLupa.pdf">http://www.bvsde.paho.org/documentosdigitales/bvsde/texcom/cd045364/TAR_BajoLupa.pdf</ext-link> [cited 2015 May 8]. Spanish.</mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="journal"><string-name><surname>Waning</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Kaplan</surname>
<given-names>W</given-names></string-name>, <string-name><surname>King</surname>
<given-names>AC</given-names></string-name>, <string-name><surname>Lawrence</surname>
<given-names>DA</given-names></string-name>, <string-name><surname>Leufkens</surname>
<given-names>HG</given-names></string-name>, <string-name><surname>Fox</surname>
<given-names>MP</given-names></string-name>. <article-title>Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databases.</article-title>
<source>Bull World Health Organ</source>. <year>2009</year>
<month>7</month>;<volume>87</volume>(<issue>7</issue>):<fpage>520</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.2471/BLT.08.058925</pub-id><pub-id pub-id-type="pmid">19649366</pub-id></mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="book">Antiretroviral treatment in the spotlight. A public health analysis in Latin America and the Caribbean 2013. Washington: Pan American Health Organization; 2013. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.paho.org/hq/index.php?option=com_docman&#x00026;task=doc_view&#x00026;gid=23710&#x00026;Itemid">http://www.paho.org/hq/index.php?option=com_docman&#x00026;task=doc_view&#x00026;gid=23710&#x00026;Itemid</ext-link> [cited 2015 May 8].</mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="journal"><string-name><surname>Muya</surname>
<given-names>AN</given-names></string-name>, <string-name><surname>Geldsetzer</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Hertzmark</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Ezeamama</surname>
<given-names>AE</given-names></string-name>, <string-name><surname>Kawawa</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Hawkins</surname>
<given-names>C</given-names></string-name>, <etal>et al.</etal>
<article-title>Predictors of nonadherence to antiretroviral therapy among HIV-infected adults in Dar Es Salaam, Tanzania.</article-title>
<source>J Int Assoc Provid AIDS Care</source>. <year>2015</year>
<month>3</month>;<volume>14</volume>(<issue>2</issue>):<fpage>163</fpage>&#x02013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1177/2325957414539193</pub-id><pub-id pub-id-type="pmid">24966305</pub-id></mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal"><string-name><surname>Ahonkhai</surname>
<given-names>AA</given-names></string-name>, <string-name><surname>Noubary</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Munro</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Stark</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Wilke</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Freedberg</surname>
<given-names>KA</given-names></string-name>, <etal>et al.</etal>
<article-title>Not all are lost: interrupted laboratory monitoring, early death, and loss to follow-up (lost to follow-up) in a large South African treatment program.</article-title>
<source>PLoS ONE</source>. <year>2012</year>;<volume>7</volume>(<issue>3</issue>):<fpage>e32993</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0032993</pub-id><pub-id pub-id-type="pmid">22427925</pub-id></mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal"><string-name><surname>Horberg</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Hurley</surname>
<given-names>LB</given-names></string-name>, <string-name><surname>Silverberg</surname>
<given-names>MJ</given-names></string-name>, <string-name><surname>Klein</surname>
<given-names>DB</given-names></string-name>, <string-name><surname>Quesenberry</surname>
<given-names>CP</given-names></string-name>, <string-name><surname>Mugavero</surname>
<given-names>MJ</given-names></string-name>. <article-title>Missed office visits and risk of mortality among HIV-infected subjects in a large healthcare system in the United States.</article-title>
<source>AIDS Patient Care STDS</source>. <year>2013</year>
<month>8</month>;<volume>27</volume>(<issue>8</issue>):<fpage>442</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1089/apc.2013.0073</pub-id><pub-id pub-id-type="pmid">23869466</pub-id></mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="web">Countries [Internet]. Geneva: Joint United Nations Programme on HIV/AIDS; 2015. Available from <ext-link ext-link-type="uri" xlink:href="http://www.unaids.org/en/regionscountries/countries">http://www.unaids.org/en/regionscountries/countries</ext-link> [cited 2014 Aug 19].</mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="web">Data. Latin America &#x00026; Caribbean (developing only) [Internet]. Washington: World Bank; 2015. Available from: <ext-link ext-link-type="uri" xlink:href="http://data.worldbank.org/region/LAC">http://data.worldbank.org/region/LAC</ext-link> [cited 2014 Jul 25].</mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="web">Countries [Internet]. Geneva: World Health Organization; 2015. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/countries/">http://www.who.int/countries/</ext-link> [cited 2014 Jul 25].</mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="journal"><string-name><surname>Rouzier</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Severe</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Juste</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Peck</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Perodin</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Severe</surname>
<given-names>P</given-names></string-name>, <etal>et al.</etal>
<article-title>Cholera vaccination in urban Haiti.</article-title>
<source>Am J Trop Med Hyg</source>. <year>2013</year>
<month>10</month>;<volume>89</volume>(<issue>4</issue>):<fpage>671</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.4269/ajtmh.13-0171</pub-id><pub-id pub-id-type="pmid">24106194</pub-id></mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="journal"><string-name><surname>Tuboi</surname>
<given-names>SH</given-names></string-name>, <string-name><surname>Schechter</surname>
<given-names>M</given-names></string-name>, <string-name><surname>McGowan</surname>
<given-names>CC</given-names></string-name>, <string-name><surname>Cesar</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Krolewiecki</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Cahn</surname>
<given-names>P</given-names></string-name>, <etal>et al.</etal>
<article-title>Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout Latin America and the Caribbean.</article-title>
<source>J Acquir Immune Defic Syndr</source>. <year>2009</year>
<month>8</month>
<day>15</day>;<volume>51</volume>(<issue>5</issue>):<fpage>615</fpage>&#x02013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1097/QAI.0b013e3181a44f0a</pub-id><pub-id pub-id-type="pmid">19430306</pub-id></mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="journal"><string-name><surname>Mermin</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Ekwaru</surname>
<given-names>JP</given-names></string-name>, <string-name><surname>Were</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Degerman</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Bunnell</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Kaharuza</surname>
<given-names>F</given-names></string-name>, <etal>et al.</etal>
<article-title>Utility of routine viral load, CD4+ cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial.</article-title>
<source>BMJ</source>. <year>2011</year>
<month>11</month>
<day>9</day>;<volume>343</volume>:<fpage>d6792</fpage>. <pub-id pub-id-type="doi">10.1136/bmj.d6792</pub-id><pub-id pub-id-type="pmid">22074711</pub-id></mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="journal"><string-name><surname>Estill</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Aubri&#x000e8;re</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Egger</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Johnson</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Wood</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Garone</surname>
<given-names>D</given-names></string-name>, <etal>et al.</etal>; <collab>IeDEA Southern Africa</collab>. <article-title>Viral load monitoring of antiretroviral therapy, cohort viral load and HIV transmission in Southern Africa: a mathematical modelling analysis.</article-title>
<source>AIDS</source>. <year>2012</year>
<month>7</month>
<day>17</day>;<volume>26</volume>(<issue>11</issue>):<fpage>1403</fpage>&#x02013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1097/QAD.0b013e3283536988</pub-id><pub-id pub-id-type="pmid">22421243</pub-id></mixed-citation></ref><ref id="R31"><label>31</label><mixed-citation publication-type="journal"><string-name><surname>Gale</surname>
<given-names>HB</given-names></string-name>, <string-name><surname>Gitterman</surname>
<given-names>SR</given-names></string-name>, <string-name><surname>Hoffman</surname>
<given-names>HJ</given-names></string-name>, <string-name><surname>Gordin</surname>
<given-names>FM</given-names></string-name>, <string-name><surname>Benator</surname>
<given-names>DA</given-names></string-name>, <string-name><surname>Labriola</surname>
<given-names>AM</given-names></string-name>, <etal>et al.</etal>
<article-title>Is frequent CD4+ T-lymphocyte count monitoring necessary for persons with counts &#x0003e;=300 cells/&#x003bc;L and HIV-1 suppression?</article-title>
<source>Clin Infect Dis</source>. <year>2013</year>
<month>5</month>;<volume>56</volume>(<issue>9</issue>):<fpage>1340</fpage>&#x02013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1093/cid/cit004</pub-id><pub-id pub-id-type="pmid">23315315</pub-id></mixed-citation></ref><ref id="R32"><label>32</label><mixed-citation publication-type="journal"><string-name><surname>Whitlock</surname>
<given-names>GG</given-names></string-name>, <string-name><surname>Ahmed</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Benn</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Edwards</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Waters</surname>
<given-names>L</given-names></string-name>. <article-title>Stop routine CD4+ cell count monitoring in HIV-infected patients with fully suppressed virus and CD4+ cell count &#x0003e;=350 cells/ml.</article-title>
<source>Clin Infect Dis</source>. <year>2013</year>
<month>7</month>;<volume>57</volume>(<issue>2</issue>):<fpage>327</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1093/cid/cit203</pub-id><pub-id pub-id-type="pmid">23537910</pub-id></mixed-citation></ref><ref id="R33"><label>33</label><mixed-citation publication-type="journal"><string-name><surname>Sax</surname>
<given-names>PE</given-names></string-name>. <article-title>Editorial commentary: can we break the habit of routine CD4+ cell count monitoring in HIV care?</article-title>
<source>Clin Infect Dis</source>. <year>2013</year>
<month>5</month>;<volume>56</volume>(<issue>9</issue>):<fpage>1344</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1093/cid/cit008</pub-id><pub-id pub-id-type="pmid">23315314</pub-id></mixed-citation></ref><ref id="R34"><label>34</label><mixed-citation publication-type="confproc">Young B, Debes R, Buchacz K, Scott M, Palella F, Brooks J, et al. HIV viral load monitoring frequency and risk of treatment failure among immunologically stable HIV-infected patients prescribed combination antiretroviral therapy. Poster WEPE045. In: 20th International AIDS Conference; 2014 Jul 20&#x02013;25; Melbourne, Australia.</mixed-citation></ref><ref id="R35"><label>35</label><mixed-citation publication-type="journal"><string-name><surname>Buscher</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Mugavero</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Westfall</surname>
<given-names>AO</given-names></string-name>, <string-name><surname>Keruly</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Moore</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Drainoni</surname>
<given-names>ML</given-names></string-name>, <etal>et al.</etal>
<article-title>The association of clinical follow-up intervals in HIV-infected persons with viral suppression on subsequent viral suppression.</article-title>
<source>AIDS Patient Care STDS</source>. <year>2013</year>
<month>8</month>;<volume>27</volume>(<issue>8</issue>):<fpage>459</fpage>&#x02013;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1089/apc.2013.0105</pub-id><pub-id pub-id-type="pmid">23886048</pub-id></mixed-citation></ref></ref-list></back></article>